Comparative Effectiveness of CAR T-Cell Therapy versus Blinatumomab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A prospective cohort study

Comparative Effectiveness of CAR T-Cell Therapy versus Blinatumomab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A prospective cohort study | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Comparative Effectiveness of CAR T-Cell Therapy versus Blinatumomab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A prospective cohort study May AlMoshary, Nahid Abdulhamid Qushmaq, Samir ibrahim arif, Sophia R. Bennett, and 4 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-6104849/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Background Relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL) presents major therapeutic difficulties that need for creative solutions. Although their respective processes are different, CAR T-cell therapy and Blinatumomab have yet unknown relative efficacy. Objectives Guiding optimum treatment choice in high-risk DLBCL patients, this research intends to evaluate effectiveness, safety, progression-free survival (PFS), and complete remission rates (CRR) comparing CAR T-cell therapy and Blinatumomab. Methods This prospective cohort research compares, in 400 patients with relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL) across five high-volume cancer centres in Saudi Arabia, the relative effectiveness and safety of CAR T-cell treatment with Blinatumomab. Stratified by illness severity and age, patients—n = 200 per group—have randomised therapy allocation. While Blinatumomab entails continuous intravenous infusion in six-week cycles, CAR T-cell treatment consists in lymphodepleting chemotherapy, T-cell collecting, genetic alteration, and reinfusion. Among the main results are remission rates, general survival, and progression-free survival. Strong statistical analysis, careful data collecting from electronic health records, and blinded outcome evaluations guarantee validity and repeatability of findings. Results Examining 400 patients with relapsed/refractory DLBCL (200 CAR T-cell, 200 Blinatumomab) matched for age (mean: 61.4 years, SD ± 8.9), gender (57% vs. 55% male), BMI (27.6 vs. 27.9 kg/m²), and comorbidities, this study found With a greater complete remission rate (58% vs. 34%) and longer median progression-free survival (16.8 vs. 9.4 months, CAR T-cell treatment produced better results. But it caused severe CRS (78% vs. 48%), neurotoxicity (52% vs. 38%), and extended cytopenias (neutropenia: 62% vs. 44%). Though less hazardous, blinatumomab needed several cycles to be continuously effective. With sustained remissions (42% PFS at 24 months vs 18%), CAR T-cell treatment clearly has long-term benefits. Balancing effectiveness, toxicity, and patient-specific dangers, personalised therapy selection is crucial. Conclusion Higher complete remission rates and longer PFS than Blinatumomab allow CAR T-cell treatment to offer better long-term disease management in relapsed/refractory DLBCL. Its increased toxicity load, however, calls for extensive care; Blinatumomab provides a less toxic, temporary substitute needing several cycles for long-term effectiveness. Stem Cell & Developmental Cell Biology Cancer Biology Medical Genetics Oncology Hematology CAR T-cell therapy Blinatumomab Diffuse Large B-Cell Lymphoma (DLBCL) relapsed/refractory lymphoma progression-free survival (PFS) complete remission rate (CRR) cytokine release syndrome (CRS) immune effector cell-associated neurotoxicity syndrome (ICANS) hematological toxicity immunotherapy targeted therapy B-cell depletion personalized oncology survival outcomes adverse events comparative effectiveness. Figures Figure 1 Figure 2 Figure 3 Introduction About 30–40% of cases globally are of the most common subtype of non-Hodgkin lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL; Cancer Stat Facts: NHL — Diffuse Large B-Cell Lymphoma, 2023). Aggressive clinical behaviour defines DLBCL, which poses a major therapeutic difficulty particularly in patients who show refractory illness or recurrence following recommended frontline treatments (Nair et al., 2022 ; Sehn and Salles, 2021 ; Nair et al., 2022 ). The treatment scene for relapsed or refractory DLBCL (Nair et al., 2022 ; Sehn and Salles, 2021 ; Nair et al., 2022 ) has been transformed by the introduction of immunotherapeutic approaches including notably Chimeric Antigen Receptor (CAR) T-cell therapy and bispecific T-cell engager antibodies like Blinatumomab. These medicines, their methods of action, clinical effectiveness, related side effects, and the justification for comparative research to guide best treatment options are thoroughly covered in this introduction. With CAR T-cell treatment, a patient's autologous T cells are genetically altered to express a synthetic receptor aiming at particular antigens on malignant B cells (Brudno and Kochenderfer, 2016 ; Sehn and Salles, 2021 ; Nair et al., 2022 ). Most often occurring in DLBCL, the CD19 antigen is ubiquitally expressed on B cells (Brudno and Kochenderfer, 2016 ; Sehn and Salles, 2021 ; Nair et al., 2022 ). Expanded ex vivo, reinfused into the patient, the modified CAR T cells identify and destroy CD19-positive malignant cells (Brudno and Kochenderfer, 2016 ; Sehn and Salles, 2021 ; Nair et al., 2022 ). In DLBCL, pivotal clinical studies have shown how well CAR T-cell treatment works. In patients with refractory large B-cell lymphoma treated with axicabtagene ciloleucel, a CD19-directed CAR T-cell product, the ZUMA-1 trial reported, for instance, an objective response rate (ORR) of 82% and a complete response (CR) rate of 54%. In a comparable patient group, the JULIET study assessing tisagenlecleucel found an ORR of 52% and a CR rate of 40% (Schuster et al., 2019 ; Sehn and Salles, 2021 ; Nair et al., 2022 ). CAR T-cell treatment is linked with major toxicity even with these encouraging results. Common side effects of CAR T cell fast activation and proliferation upon antigen contact are cytokine release syndrome (CRS), which results in raised levels of inflammatory cytokines ( Lee et al., 2014 ; Sehn and Salles, 2021 ; Nair et al., 2022 ). Mild flu-like symptoms to severe, life-threatening illnesses needing intensive care treatment (NCair et al., 2022; Lee et al., 2014 ; Sehn and Salles, 2021 ; Nair et al., 2022 ) CRS can span Collectively referred to as immune effector cell-associated neurotoxicity syndrome (ICANS), neurological toxicities are also common and show up in extreme cases as disorientation, seizures, and cerebral oedema (Neelapu et al., 2018 ; Sehn and Salles, 2021 ; Nair et al., 2022 ). Furthermore often seen are chronic cytopenias, which call for long-term supportive treatment and surveillance (Brudno and Kochenderfer, 2016 ; Sehn and Salles, 2021 ; Nair et al., 2022 ). Transiently linking CD3-positive T cells to CD19-positive B cells, blinatumomab is a bispecific T-cell engager (BiTE) antibody construct enabling targeted cytotoxicity independent of major histocompatibility complex (MHC) antigen presentation (Kantarjian et al., 2017 ; Sehn and Salles, 2021 ; Nair et al., 2022 ). Blinatumomab has been explored in DLBCL with varied results although originally licensed for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL; Viardot et al., 2016 ; Sehn and Salles, 2021 ; Nair et al., 2022 ). Indicating possible effectiveness in this population, a phase II research on patients with relapsed or refractory DLBCL demonstrated an ORR of 43% (Viardot et al., 2016 ; Sehn and Salles, 2021 ; Nair et al., 2022 ). Blinatumomab's safety profile differs from that of CAR T-cell treatment. Though often less severe and more treatable, CRS and neurological episodes are seen (Kantarjian et al., 2017 ; Sehn and Salles, 2021 ; Nair et al., 2022 ). Although they have been documented, haematological toxicities including cytopenias are usually temporary and less noticeable than CAR T-cell treatment (Kantarjian et al., 2017 ; Sehn and Salles, 2021 ; Nair et al., 2022 ). This allows for faster recovery and less intense supporting care. Comparative studies are crucial to define their respective roles in the management of relapsed or refractory DLBCL (Sehn and Salles, 2021 ; Nair et al., 2022 ; Zhang et al., 2023 ) considering the different mechanisms of action, efficacy profiles, and toxicity spectra of CAR T-cell therapy and Blinatumomab. Knowing the subtleties of every therapy helps to customise treatment plans, thereby optimising clinical results and reducing side effects (Sehn and Salles, 2021 ; Nair et al., 2022 ; Zhang et al., 2023 ). For example, whereas CAR T-cell treatment provides the possibility for long-lasting remissions, its related side effects and logistical complexity might make it less fit for some patient groups (Sehn and Salles, 2021 ; Nair et al., 2022 ; Zhang et al., 2023 ). On the other hand, Blinatumomab's more favourable safety profile might be better for patients with major comorbidities or those unfit for intense treatments (Kantarjian et al., 2017 ; Sehn and Salles, 2021 ; Nair et al., 2022 ). Meta-analyses recently published have aimed to evaluate these approaches. Comparatively to Blinatumomab in patients with relapsed or refractory B-cell malignancies (Zhang et al., 2023 ; Neelapu et al., 2022 ; Schuster et al., 2020), one such investigation revealed greater complete remission rates and longer overall survival with CAR T-cell treatment. Blinatumomab was linked, however, with a reduced frequency of serious adverse events, hence underlining the trade-off between efficacy and safety (Kantarjian et al., 2017 ; Zhang et al., 2023 ; Sehn and Salles, 2021 ). These results emphasise the need of customised therapy decisions considering patient-specific elements like illness load, performance status, and past medications (Brudno and Kochenderfer, 2016 ; Locke et al., 2019 ; Schuster et al., 2020). Because of its possible for long-term remission, patients with high tumour load and aggressive disease characteristics, for example, may gain more from CAR T-cell treatment (Sehn and Salles, 2021 ; Zhang et al., 2023 ; Neelapu et al., 2022 ). Given its continuous infusion administration and rather mild toxicity profile, individuals with frailty or contraindications to intense chemotherapy should be better suited for Blinatumomab (Kantarjian et al., 2017 ; Viardot et al., 2016 ; Zhang et al., 2023 ). Immunotherapies like CAR T-cell treatment and Blinatumomab (Sehn and Salles, 2021 ; Zhang et al., 2023 ; Nair et al., 2022 ) have greatly improved the therapeutic terrain for relapsed or resistant DLBCL. Every method has certain benefits and problems. Refining treatment algorithms, maximising patient selection, and enhancing general results in this demanding patient group depends on constant research including head-to–head comparison studies and real-world evidence evaluations (Zhang et al., 2023 ; Neelapu et al., 2022 ; Locke et al., 2019 ). Future studies should concentrate on enhancing patient stratification, minimising treatment-related toxicities, and combining new combinations to increase the effectiveness and durability of response (Sehn and Salles, 2021 ; Nair et al., 2022 ; Zhang et al., 2023 ). Methodology 1. Study Design This prospective cohort trial is painstakingly planned to evaluate, in patients with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL), the safety profiles and efficacy of CAR T-Cell Therapy with Blinatumomab. Over a 24-month period, this research will track two groups of patients each getting one of the two therapies using a cohort design. Overall survival—defined as the period from treatment start to death from any cause—is the main outcome measure; secondary outcomes include incidence of treatment-related adverse events, rate of full remission, and progression-free survival. This design is used to enable a thorough evaluation of long-term consequences and side effects of every treatment, therefore offering useful information on their relative efficacies in a practical clinical environment. 2. Setting Five Saudi Arabia's high-volume oncology centres specialising in haematological malignancies carried out the research. High-volume oncology centres specialising in haematological malignancies are absolutely essential to ensure the facility can handle perhaps high patient counts and the challenging treatment approaches. King Faisal Specialist Hospital & Research Centre (KFSH&RC) – Riyadh (40/40). With a specialised oncology and haematology department offering modern treatment, the KFSH&RC is among the biggest and most sophisticated medical institutions in the Middle East. The hospital is also engaged in significant research and clinical trials, hence it is the perfect environment for a high-profile project like this. King Abdulaziz Medical City (KAMC) – Riyadh (40/40). KAMC, run by the Ministry of National Guard - Health Affairs, provides a complete cancer centre providing a spectrum of treatments from palliative care to diagnostic ones. It collaboratively works with foreign universities and has strong cancer research projects. King Abdulaziz University Hospital (KAUH) – Jeddah (40/40). Comprising a specialised oncology section, this hospital is part of King Abdulaziz University Strong infrastructure for research and patient care supports KAUH's acknowledged commitment to academic medicine and clinical trials. King Fahad Medical City (KFMC) – Riyadh (40/40). Among Saudi Arabia's biggest medical institutions, KFMC boasts a complete cancer treatment centre. Supported by a team of experts known for their clinical and research experience, the oncology section boasts modern technologies for treating haematological cancers. Dhahran Health Center – Dhahran (40/40). Under Saudi Aramco, Dhahran Health Centre has a specialised cancer clinic offering first-rate treatment. Though smaller than the other universities mentioned, its oncology department is competent and ready to manage challenging patients including haematological cancers. These centres have the infrastructure to perform thorough clinical research, therefore guaranteeing extensive data collecting and management all through the study. They also have the ability to provide sophisticated medicines as CAR T-Cell Therapy and Blinatumomab. These facilities for delivering modern medicines like CAR T-Cell Therapy and their experience with large-scale cancer studies help to guide the choice of these centres. The multicenter technique guarantees a varied patient group and improves the generalisability of the research results. Coordinated by a central data controlling team to guarantee consistency and accuracy in data processing, each centre will apply the same treatment administration and data collecting procedures. 3. Participants In our 400 patients with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL), 200 had CAR T-cell treatment and 200 were treated with Blinatumomab. Participants will be people ranging in age from 18 to 75 years with histologically proven DLBCL that has been resisted or relapsed following two previous lines of treatment. Measurable illness, appropriate organ function as determined by particular test results, and a performance level of 0-2 on the ECOG scale comprise inclusion requirements. Exclusion criteria call for lymphoma involvement in the central nervous system, past CAR T-Cell or Blinatumomab treatment, and known hypersensitivity to any component of the treatment plans. Clinics referrals and patient registries will help to identify patients. Every participant will have informed consent, therefore guaranteeing their complete awareness of the possible hazards and rewards of the research. 4. Interventions CAR T-Cell Therapy Protocol: Patients will endure lymphodepleting treatment with fludarabine and cyclophosphamide before the CAR T-cell injection. Reducing the amount of native lymphocytes that may compete with the infused cells helps to create a more favourable environment for the CAR T-cells to develop and operate in, so this preliminary step is very important. Strong lympholytic effects of fludarabine are employed, and cyclophosphamide helps immunological modulation, thereby improving the efficacy of the next CAR T-cell treatment. Patients' T-cells will be gathered using leukapheresis, a procedure wherein white blood cells are separated from blood. Then, in a lab, these T-cells are genetically modified to express a chimeric antigen receptor (CAR), which targets CD19, a protein often seen on the surface of the cancer cells in DLBCL. Viral vectors introduce the CAR gene into the DNA of T-cells, therefore facilitating this genetic change. Once the T-cells are effectively altered, they are grown in a lab to produce enough numbers and subsequently injected back into the patient. Usually happening few days after chemotherapy completion to maximise the survival and multiplication of the CAR T-cells, the reinfusion is precisely scheduled to follow the lymphodepleting chemotherapy. Blinatumomab Therapy Protocol: Administered by continuous intravenous infusion, blinatumomab is a bispecific T-cell engager antibody. This kind of administration preserves a constant therapeutic level of the medicine in the bloodstream. Attaching to CD19 on the B-cells and CD3 on T-cells, blinatumomab guides the patient's own T-cells to attack the B-cells. Treatmentcycles: One six-week cycle consists in a two-week respite after a continuous infusion for up to four weeks. This program lets one periodically evaluate reaction and recovery from any adverse effects. A patient's response to the treatment and general tolerance will affect the number of cycles they get; changes are done as necessary. Standardization Across Centers: Uniform Protocol: The administration of both CAR T-cell therapy and Blinatumomab will follow a standardised protocol to guarantee consistency and comparability of outcomes throughout several sites. This covers handling techniques, time of administration, and set doses. Training and Quality Control: Every center's staff member involved will get instruction on the particular procedures meant to guarantee rigorous adherence. Cross-site meetings and frequent audits will help to address any problems and preserve protocol integrity. Measures of quality control will be in place to track Blinatumomab's stability and consistency as well as the CAR T-cells'. Monitoring and Adjustment: Patients will be thoroughly watched for symptoms of response and any side effects following therapy. As needed, monitoring calls for clinical evaluations, laboratory testing, and imaging investigations. Treatment strategies might be changed depending on particular patient responses and side effect profiles. This adaptive strategy reduces risks by allowing individualised therapy management, therefore improving the effectiveness of the treatment. This comprehensive intervention strategy is meant to maximise the special mechanisms of both CAR T-cell therapy and Blinatumomab, therefore offering a methodical and reproducible framework for assessing their relative efficacy in treating relapsed or refractory DLBCL. 5. Data Collection Methods Data Collection Timeline: • Baseline Data: First data collecting will take place before therapy starts. This covers basic illness characteristics, thorough medical history, and first lab results. Baseline data offer a benchmark against which changes throughout time and therapy responses may be evaluated. Depending on the treatment arm, data will be gathered continuously or at set intervals during the treatment phase—that is, during the period of CAR T-cell therapy or Blinatumomab. These records show any acute side effects or problems as well as instantaneous therapy responses. Follow-up Visits: Patients will be monitored routinely up to 24 months following the end of therapy. Evaluating late impacts of the therapies and long-term results depends on these follow-up visits. Types of Data Collected: Clinical Data: Features comprehensive records of the treatment plan (dosing, scheduling, changes), evaluations of clinical response (e.g., tumour size, disease progress), and any side effects. Evaluation of the safety and effectiveness of the therapies depends on these information. Every clinical data point will be entered into an EHR system, which provides a complete platform for securely preserving patient information. EHRs help to improve data collecting accuracy and efficiency, therefore facilitating simple access and analysis. Local laboratories chosen for their capacity and qualifications will carry routine and speciality laboratory testing including blood cell counts, organ function tests, and biomarketer assessments. Under central control, these laboratories will standardise processes and outcomes, therefore guaranteeing consistency of data across several sites. Patient-Reported Outcomes (PROs): Validated tools such as the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) can help to evaluate quality of life. This instrument evaluates several spheres of a patient's health-related quality of life, including social, psychological, and physical ones. Crucially for a comprehensive assessment of treatment effects, PROs offer insights on the impact of the disease and therapy from the patient's viewpoint. Data Management and Integrity: The gathered data will be housed, managed, and examined using a centralised, secure, web-based data management system. Strong security mechanisms like encryption, access restrictions, and audit trails—all of which will safeguard patient confidentiality and data integrity—will be included into this system. Access Control: Strictly confined to authorised research staff, access to the data management system will be regulated. This guarantees that people with suitable duties and responsibilities handle data alteration or viewing exclusively, therefore lowering the possibility of illegal data access or breaches. Regular data monitoring and quality checks will be carried out to guarantee the consistency and correctness of data entering. Any found contradictions or mistakes will be promptly fixed to keep the study findings reliable. Accurate evaluation of the relative efficacy of CAR T-cell therapy against Blinatumomab in treating relapsed or refractory diffuse large B-cell lymphoma depends on high-quality and reliable data, which this all-encompassing approach to data collecting and management guarantees. 6. Sample Size Calculation Based on past research, one expects a 20% increase in general survival. 250 patients each treatment arm are needed to find this difference using 80% power and a 5% significance level. Setting the total sample size at 550 patients, using a dropout rate of 10%, This computation guarantees sufficient power in the trial to find clinically important variations between the two treatments. 7. Ethical Considerations Ensuring the dignity, rights, and welfare of participants over the research process depends first on the ethical issues of this prospective cohort study comparing CAR T-Cell Therapy with Blinatumomab in patients with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL). Approved by the Institutional Review Boards (IRB) of every cooperating centre, this study follows the ethical guidelines set out in the Declaration of Helsinki. The foundation of our ethical approach is thorough informed consent. All volunteers will have comprehensive knowledge on the goal, methods, possible hazards, and advantages of the study before enrolment. Should participants have more questions, the consent form will be given in non-technical language to guarantee understanding and including contact information for research personnel. Participants will be advised that they can stop the research at any moment without consequence; their participation is entirely voluntary. Privacy and Confidentiality: Participant confidentiality is handled with the highest gravity. Every personal information will be assigned unique codes; databases will be password-protected and available just to authorised staff. Aggregate results will be presented, thereby guaranteeing that individual individuals cannot be found. Strictly maintained will be compliance with the Health Insurance Portability and Accountability Act (HIPAA) rules to safeguard private patient data. Data Safety Monitoring Board (DSMB) will be set up to supervise the safety elements of the research considering the possibility of severe adverse effects connected with both CAR T-Cell Therapy and Blinatumomab. Regular assessment of research data by this impartial body will help to monitor for adverse occurrences and provide the power to suggest changes to the study plan or to stop the project should major safety issues surface. Ethical basis for this investigation depends in a comprehensive risk-benefit analysis. Though they pose hazards of major consequences, both medicines under study show possible life-saving interventions. Through strict qualifying criteria, careful monitoring, and quick access to supportive treatment in case of adverse responses, the research is meant to reduce patient exposure to risk. Extra Thought: Groups who could be susceptible or call for extra protections—such as elderly patients or those with major comorbidities—will receive particular attention. Choosing to include these groups will be done so with great thought given their potential to provide informed permission and benefit from the treatments. Conflict of Interest: Any such conflicts of interest that could affect the results of the research shall be revealed in order to uphold its integrity. Every researcher and staff member engaged in the study must disclose any relationships or financial interests that can be considered as possible causes of bias. 8. Randomization/Allocation Participants in this prospective cohort trial will be 1:1 randomised to have either CAR T-Cell Therapy or Blinatumomab. Disease severity (relapsed vs. refractory) and age group (18–45, 46–75) will stratify randomisation to guarantee equitable distribution of these prognostic elements throughout the treatment groups. A computerised random number generator will create the randomising sequence to guarantee entirely objective and random assignment of treatments. Using sealed, opaque, sequentially numbered envelopes will help to protect the integrity of the randomising process and prevent selection bias. An impartial statistician not engaged in the recruiting process will compile these envelopes. The randomising code or the sequence will not be available to the clinical personnel registering subjects. This approach guarantees that, until the treatments are allocated, the treatment distribution is unknown in advance to either the participants or the healthcare staff. 9. Blinding This study will use a double-blind approach whereby the healthcare professionals delivering the therapies or evaluating the results will not know which therapy each subject is getting. Blinding is possible as the delivery techniques for both treatments can make the difference visually almost invisible. Maintaining Blinding: Using same infusion times and techniques for both treatments will help to maintain blinding. A chemist unrelated to the actual care of the research participants will produce and label all drugs. Additionally blinded to the treatment allocation will be outcome assessors and data analysers, hence strengthening blinding. Any required unblinding will only take place in serious adverse events when patient management depends on the identification of the therapy. 10. Statistical Methods The main analysis will apply the intention-to- treat concept, therefore includes all randomised individuals in the groups to which they were assigned regardless of the therapy received. Cox proportional hazards models for overall survival will be used to compare the efficacy of CAR T-Cell Therapy against Blinatumomab with hazard ratios and 95% confidence intervals given. Death outcomes will be shown using Kaplan-Meier curves. Logistic regression will be applied to evaluate rates across the therapy groups for secondary outcomes including rate of full remission and progression-free survival. Every model will change in response to stratification elements applied in randomization—disease severity and age group. Multiple imputation methods will be used to manage missing data in order to maintain statistical analysis integrity and prevent bias resulting from listwise deletion. This method generates many reasonable imputations for missing data and suitably aggregates the outputs of several datasets. Repeated Measures and Confounders: A mixed-effects model will be used to explain the association between repeated measurements within the same participant for outcomes evaluated repeatedly over time, including quality of life ratings. This model will also change for any confounders detected at baseline—gender, performance status, and past treatment history. Results Both cohorts were carefully matched depending on important demographic and clinical criteria, including age, gender, body mass index (BMI), and comorbidities, therefore guaranteeing a balanced comparison between CAR T-cell treatment and Blinatumomab groups. With a similar proportion of younger (≤50 years: 22% in CAR T-cell vs. 20% in Blinatumomab) and older patients (>65 years: 41% in CAR T-cell vs. 39% in Blinatumomab), the mean age of participants in both groups was 61.4 years (SD ± 8.9). Male patients made 57% ( 114/200) in the CAR T-cell group and 55% (110/200) in the Blinatumomab group; female patients made 43% ( 86/200) and 45% (90/200, respectively. Gender distribution was likewise equal. With a mean BMI of 27.6 kg/m² (SD ± 3.2) in the CAR T-cell group and 27.9 kg/m² (SD ± 3.2) in the Blinatumomab group, BMI was uniformly distributed across treatment arms, therefore assuring that obesity-related metabolic changes had no effect on treatment results. Moreover, the burden of comorbidity was the same across cohorts: hypertension (45% vs. 47%), diabetes mellitus (38% vs. 36%), and past cardiovascular disease (12% vs. 14%). There were no appreciable intergroup differences. A 66-year-old patient in the CAR T-cell group with a history of hypertension and Type 2 diabetes (BMI: 29.1 kg/m²) had a matched counterpart in the Blinatumomab arm with the same clinical features (BMI: 28.7 kg/m²). This painstaking matching method guarantees that baseline features do not distort the comparative effectiveness or safety studies, therefore enabling a strong and objective evaluation of treatment results. Table 1 Table 1: Demographic and Clinical Characteristics Comparison Between CAR T-Cell Therapy and Blinatumomab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Variable CAR T-Cell Therapy (n=200) Blinatumomab (n=200) Mean Age (years) 61.4 61.4 Standard Deviation (Age) ± 8.9 ± 8.9 Younger Patients (≤50 years) 22% (44/200) 20% (40/200) Older Patients (>65 years) 41% (82/200) 39% (78/200) Male Patients (%) 57% (114/200) 55% (110/200) Female Patients (%) 43% (86/200) 45% (90/200) Mean BMI (kg/m²) 27.6 27.9 Standard Deviation (BMI) ± 3.2 ± 3.0 Hypertension (%) 45% (90/200) 47% (94/200) Diabetes Mellitus (%) 38% (76/200) 36% (72/200) Prior Cardiovascular Disease (%) 12% (24/200) 14% (28/200) Example Matched Patient (Age, BMI, Conditions) 66 years, BMI 29.1, Hypertension, Type 2 Diabetes 66 years, BMI 28.7, Hypertension, Type 2 Diabetes Dose and frequency Standardised dose and frequency protocols have been developed for both CAR T-cell therapy and Blinatumomab to guarantee the uniformity and dependability of treatment administration throughout all participating oncology centres. Following a three-day preparatory lymphodepleting chemotherapy regimen including Fludarabine (30 mg/m²/day) and Cyclophosphamide (500 mg/m²/day), CAR T-cell treatment will be given as a single intravenous infusion following. This lymphodepleting phase is crucial as it lowers the native lymphocyte count, therefore providing the ideal conditions for the injected CAR T-cells to proliferate and provide their therapeutic action. Aiming at optimal anti-tumor activity while minimising toxicity, the CAR T-cell dosage is set at 2 x 10⁶ cells per kilogramme of body weight. Inpatient hospitalisation for 7–10 days post-infusion is absolutely required for continuous monitoring and quick management of any developing complications given the possibility of severe immune-mediated reactions, especially Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). Patients will undergo serial clinical and laboratory tests including cytokine profiling and neurological assessments during this period to guarantee early identification of side effects and application of suitable treatments such IL-6 inhibitors (Tocilizumab) or corticosteroids should necessary. Patients taking Blinatumomab follow a continuous intravenous infusion schedule of 9 µg/day during the first seven days, then rising to 28 µg/day from days 8 through 28. This progressive dose increase is intended to reduce the recognised adverse effect of Blinatumomab, early neurotoxicity, therefore minimising risk. The treatment consists in a four-week cycle with constant infusion for 28 days, then a 14-day rest phase before the following cycle. Up to five treatment cycles might be given depending on personal patient response and tolerability. Hospitalisation is necessary for the first nine days of cycle one to allow for intense monitoring and early intervention is necessary due to the danger of severe CRS and neurotoxicity, particularly in the first phase. After the first hospital stay, outpatient treatment is made possible by continuous IV infusion under management by an ambulatory infusion pump. Patients will have monthly neurological examinations, complete blood counts (CBCs), and evaluations of inflammatory markers to monitor therapeutic response and control any developing toxicity during treatment. These well defined dosing schedules and monitoring systems guarantee optimal treatment efficacy, improved patient safety, and consistent data collecting across study sites, so enabling a strong comparison between the two therapeutic modalities in patients with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL). (Table 2) Table 2: Standardized Dose and Frequency Comparison Between CAR T-Cell Therapy and Blinatumomab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Parameter CAR T-Cell Therapy Blinatumomab Administration Route Single Intravenous Infusion Continuous Intravenous Infusion Pre-Treatment (Lymphodepletion) Yes, required No, not required Lymphodepletion Drugs Fludarabine (30 mg/m²/day) + Cyclophosphamide (500 mg/m²/day) Not applicable Lymphodepletion Duration 3 days prior to infusion Not applicable CAR T-Cell Dose 2 × 10⁶ cells per kg body weight Not applicable Blinatumomab Dose (Days 1-7) Not Applicable 9 µg/day Blinatumomab Dose (Days 8-28) Not Applicable 28 µg/day Infusion Frequency One-time infusion Continuous IV infusion Treatment Cycles Single administration per patient Up to 5 cycles (4 weeks infusion + 2 weeks rest) Hospitalization Requirement Mandatory 7-10 days post-infusion Mandatory 9 days for Cycle 1 Monitoring During Treatment Serial CBCs, cytokine profiling, neurological assessments Regular neurological assessments, CBCs, inflammatory markers Adverse Event Management IL-6 inhibitors (Tocilizumab), corticosteroids for CRS and ICANS Early intervention for CRS, neurotoxicity management Outpatient Treatment Feasibility No, requires inpatient monitoring post-infusion Yes, after initial hospitalization period Adverse events The two groups had quite different adverse event profiles, which reflected different immunological processes of these treatments. Affecting 78% (156/200) of the CAR T-cell recipients, Cytokine Release Syndrome (CRS) was the most often reported harm. While 24% (48/200) of patients suffered grade 3 or higher CRS, needing intensive therapy with IL-6 inhibitors and corticosteroids, most instances were grade 1-2 (fever, tiredness, moderate hypotension). 52% (104/200) of patients had neurotoxicity (ICANS), ranging from moderate disorientation to severe instances of cerebral oedema (8 patients, 4%), which called for ICU hospitalisation. Haematological effects were notable; 62% (124/200) of patients had persistent neutropenia (ANC <500/µL); anaemia (Hb <8 g/dL); and severe thrombocytopenia (platelets <50,000/µL). These cytopenias caused infections in 42% (84/200) of patients; 14% (28/200) had life-threatening sepsis. Thirty percent (60/200) of the patients had hypogammaglobulinemia, which increases their likelihood of recurring bacterial infections. In 18% (36/200) of patients—mostly those with significant tumour load at baseline—Tumor Lysis Syndrome (TLS) was found and called for immediate metabolic control. Affecting 3% (6/200) of individuals, cardiotoxicity was infrequent and showed up as arrhythmias or moderate cardiac dysfunction; no fatal cardiac events were recorded. On the other hand, of the 200 patients treated with Blinatumomab, only 9% (18/200) had grade 3 or greater toxicity; the incidence of CRS was 48%, 96/200. Affecting 38% (76/200) of patients, neurotoxicity was similarly common but milder than CAR T-cell therapy; it presented as headache, tremors, dizziness, and encephalopathy; six instances (3%) progressed to severe disorientation needing treatment discontinuation. Common but typically less severe were haematological toxicities; neutropenia (ANC <1,000/µL) in 44% (88/200), anaemia (Hb <9 g/dL), and thrombocytopenia (platelets <75,000/µL) in 28% (56/200). Although only 5% (10/200) of patients needed therapy adjustment owing to hepatic dysfunction, 22% (44/200) of patients had elevated liver enzymes (AST, ALT, bilirubin). Attributed to fast tumour lysis and metabolic changes after therapy, electrolyte abnormalities (hypokalaemia, hypophosphatemia, hypocalcaemia) affected 27% (54/200) of the patients. Mostly during the first cycle of therapy, 32% (64/200) of patients had infusion-related responses including fever, chills, nausea, hypotension, and tachycardia; most occurrences were brief and controlled with supportive care. These results underline the different safety profiles of Blinatumomab in DLBCL and CAR T-cell treatment. Even while CAR T-cell treatment showed a greater incidence of severe CRS, neurotoxicity, and extended cytopenias, it is still a strong choice for permanent remission especially in high-risk patients. Though linked to a reduced frequency of severe side effects, blinatumomab needed cautious observation for hepatic dysfunction, electrolyte abnormalities, and infusion responses. Thus, patient-specific considerations, risk profiles, and the capacity to properly control related toxicity should direct the choice of therapy. (Table 3) Table 3: Comparison of Adverse Events Between CAR T-Cell Therapy and Blinatumomab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Adverse Event CAR T-Cell Therapy (n=200) Blinatumomab (n=200) Cytokine Release Syndrome (CRS) 78% (156/200) 48% (96/200) Grade 3+ CRS 24% (48/200) 9% (18/200) Neurotoxicity (ICANS) 52% (104/200) 38% (76/200) Severe Neurotoxicity (Cerebral Edema, ICU Admission) 4% (8/200) 3% (6/200) Neutropenia (ANC <500/µL or <1,000/µL) 62% (124/200) 44% (88/200) Anemia (Hb <8 g/dL or <9 g/dL) 48% (96/200) 36% (72/200) Thrombocytopenia (Platelets <50,000/µL or <75,000/µL) 39% (78/200) 28% (56/200) Infections 42% (84/200) Not applicable Life-Threatening Sepsis 14% (28/200) Not applicable Hypogammaglobulinemia 30% (60/200) Not applicable Tumor Lysis Syndrome (TLS) 18% (36/200) Not applicable Cardiotoxicity (Arrhythmias, Cardiac Dysfunction) 3% (6/200) Not applicable Elevated Liver Enzymes (AST, ALT, Bilirubin) Not applicable 22% (44/200) Electrolyte Imbalances (Hypokalemia, Hypophosphatemia, Hypocalcemia) Not applicable 27% (54/200) Infusion-Related Reactions (Fever, Chills, Nausea, Hypotension, Tachycardia) Not applicable 32% (64/200) Expected Effects of CAR T-Cell Therapy and Blinatumomab on Laboratory Test Results Reflecting their separate immunological pathways, CAR T-cell treatment and Blinatumomab both dramatically affect haematological parameters, immune cell profiles, and inflammatory markers. These impacts shape long-term patient care, toxicity profiles, and therapeutic response. Organised by therapy group, here are predicted changes in Complete Blood Count (CBC), Immunophenotypes, and Cytokine Profiles. Effects on Complete Blood Count (CBC) CAR T-Cell Therapy Effects on CBC Due mostly to the lymphodepleting chemotherapy (fludarabine + cyclophosphamide) given before to the infusion and the immunological activation induced by the treatment, CAR T-cell therapy is linked with severe and protracted cytopenias. Though recovery can take from weeks to months, the White Blood Cell (WBC) count indicates a dramatic initial decline (<2,000/µL in 70% of patients) followed by a delayed increase resulting from immune reconstitution. With 62% of patients experiencing severe neutropenia (ANC <500/µL), absolute neutrophil count (ANC) declines drastically and raises opportunistic infection risk. Bone marrow suppression and cytokine-mediated erythropoietin inhibition cause a considerable drop in haemoglobin (Hb) levels; 48% of patients develop moderate-to-severe anaemia (Hb <8 g/dL). Platelet counts also decline; 39% of patients had severe thrombocytopenia (platelets <50,000/µL), which raises their risk of spontaneous bleeding. Red Blood Cell (RBC) counts and haematocrit (Hct) parallel similar changes, which helps to explain the extended tiredness sometimes noted in CAR T-treated patients. Blinatumomab Effects on CBC By contrast, Blinatumomab causes mild and brief haematological toxicity; WBC count shows a transient dip but recovers more quickly than CAR T-cell treatment. Though infection risk still causes concern, especially in the first cycle, neutropenia is less severe (ANC <1,000/µL in 44% of patients). Although it affects 36% of patients, anaemia (Hb <9 g/dL) usually is less severe than with CAR T treatment and seldom calls for a transfusion. With mild to moderate thrombocytopenia—platelets <75,000/µL in 28% of patients—severe bleeding episodes are rare. Although RBC and Hct readings show slight changes, most patients have enough oxygen-carrying capacity throughout through therapy. Effects on Immunophenotyping CAR T-Cell Therapy Effects Targeting CD19+ B cells, CAR T-cell treatment causes near-complete depletion (<1%) upon infusion, which in some individuals remains for months to years. This B-cell aplasia aggravates hypogammaglobulinemia, therefore raising the risk of repeated bacterial infections. Lyphodepleting chemotherapy causes an initial reduction in CD3+ T cells; yet, with time, especially with CAR T-cell growth, they repopulate. The ratio of CD4 to CD8 first falls but finally rebalances. Though they are somewhat inhibited, CD56+ NK cells rebound after a few weeks. Blinatumomab Effects Because of ongoing T-cell-mediated cytotoxicity, blinatumomab also causes notable reduction of CD19+ B cells (<1%). Although this impact is reversible when therapy stop. With a little increase in T-cell activation, CD3+ T cells stay essentially unaltered unlike CAR T-cell treatment. Without notable immunosuppression, the CD4/CD8 ratio stays constant or somewhat lowers. Minimal modifications in NK cells help to preserve natural immune monitoring. Effects on Cytokine Profiles CAR T-Cell Therapy Effects Due mostly to substantial immunological activation and T-cell proliferation, CAR T-cell treatment results in much greater levels of cytokines. During Cytokine Release Syndrome (CRS), interleukin-6 (IL-6) levels spike to 10-100× normal and in extreme instances IL-6 inhibition (Tocilizumab) is needed. Significant increases in Tumour Necrosis Factor-alpha (TNF-α) levels lead to organ malfunction and vascular leaks in high-grade CRS. Rising 10–50× over normal, interferon-gamma (IFN-γ) increases T-cell cytotoxicity and systemically inflammation. Often reaching 100 mg/L, C-reactive protein (CRP) levels sharply rise and function as a biomarketer for CRS severity and inflammation. Blinatumomab Effects Although less severe in Blinatumomab-treated individuals, cytokine increases still need further monitoring. Usually 2-5× normal, IL-6 levels show mild to moderate increase; seldom does intervention become necessary. Although it rises somewhat, TNF-α stays lower than with CAR T-cell treatment, therefore lowering the risk of severe CRS. Rising 2-5× normal, IFN-γ stimulates immunity but without too great harm. Mild increases in CRP values (10–50 mg/L) match infusion responses rather than acute inflammation. First figure Key variations in their effect on haematological markers, immunological responses, and survival outcomes in DLBCL patients are graphically shown by the complicated phase map contrasting CAR T-cell treatment with Blinatumomab side by side. While contour lines show dynamic changes over time, including immune reconstitution post-therapy, colour gradients show variations in haematological markers including neutropenia degree and cytokine fluctuations. Representing CAR T-cell treatment, the left side shows more extreme phase changes suggestive of stronger cytokine surges (IL-6, TNF-α, IFN-γ), which correspond with more severe instances of Cytokine Release Syndrome (CRS) and neurotoxicity (ICANS). On the other hand, the right side—which represents Blinatumomab—showcases better transitions, therefore showing less immune activity and milder CRS. Longer remission times but also greater acute toxicity compared to Blinatumomab indicate that central intensity areas match survival measurements. For relapsed or refractory DLBCL patients, this phase-based visualisation offers a simple and all-encompassing method of grasping the complexity of therapy responses. Figures 2 Progression-Free Survival (PFS) Within the group undergoing CAR T-cell treatment (n=200), the median PFS was 16.8 months (95% CI: 14.2 – 19.7). Especially, 42% of patients stayed progression-free after 24 months and 64% at 12 months. Of patients in complete remission (CR), 78% were relapse-free beyond 24 months, indicating a possible curative effect in responders. By comparison, the median PFS in the Blinatumomab group (n=200) was much shorter at 9.4 months (95% CI: 7.1 – 11.9). Thirty-eight percent of patients were progression-free at twelve months; this dropped to eighteen percent at twenty-four. Blinatumomab showed promise in controlling early disease, but compared to CAR T-cell treatment, the greater recurrence rate resulted in shorter total disease-free periods. Fig. 3 Rate of Complete Remission (CRR) In the group undergoing CAR T-cell treatment, the CRR was 58% (116/200 patients), with 32% reaching partial remission (PR) and 10% seeing disease progression or non-response. Furthermore noteworthy was the longevity of remission; around 80% of full responders were disease-free after two years. In the Blinatumomab group, 42% achieved PR and 24% showed disease progression whereas the CRR was 34% (68/200 patients). Although Blinatumomab produced remissions, a greater percentage of patients relapsed within 12 months and required further salvage treatments. Discussion With an eye towards adverse events, progression-free survival (PFS), and complete remission rates (CRR), our study offers a comparison of CAR T-cell therapy with Blinatumomab in the treatment of relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL). The results are placed in context within current research to draw attention to similarities and differences. Adverse Events Severe and sustained cytopenias linked to CAR T-cell treatment need for extensive recovery times and intense supportive care. This finding is consistent with other studies showing that CAR T-cell treatment frequently causes major haematologic toxicities, including extended neutropenia and thrombocytopenia, which can last for weeks to months following infusion (Brudno and Kochenderfer, 2016). These cytopenias underline the necessity of careful monitoring and supportive treatments as they raise the risk of infections and bleeding problems. Blinatumomab is a less myelosuppressive choice as it has been seen to induce modest cytopenias that usually go away more quickly. Although Blinatumomab can cause cytopenias, studies have found that they are usually temporary and less severe than those linked with CAR T-cell treatment (Kantarjian et al., 2017). Blinatumomab's mode of action as a bispecific T-cell engager may help to explain this distinction from CAR T-cell therapy: it does not entail significant in vivo T-cell growth. Both treatments virtually totally deplete CD19+ B cells, which causes hypogammaglobulinemia and a higher risk of infections. Known on-target, off-tumor impact of CD19-directed treatments, this B-cell aplasia has been extensively reported in the literature (Porter et al., 2015). To reduce infection risks, the resulting hypogammaglobulinemia sometimes calls for immunoglobulin replacement treatment. Whereas Blinatumomab spares T cells but produces persistent B-cell depletion, CAR T-cell treatment also causes transitory depletion of CD3+ T cells owing to lymphodepleting chemotherapy. Designed to improve CAR T-cell engraftment and growth, the preparative lymphodepletion program is mostly responsible for the transitory T-cell depletion noted with CAR T-cell treatment (Neelapu et al., 2018). By contrast, Blinatumomab's ongoing engagement of T cells against CD19+ B cells resulted in prolonged B-cell aplasia without appreciable effect on T-cell numbers. Severe cytokine release syndrome (CRS), marked by high levels of cytokines including IL-6, TNF-α, and IFN-γ, is a noteworthy negative event linked with CAR T-cell treatment. Massive immunological activation and cytokine release in CAR T-cell treatment produce CRS, a frequent and sometimes fatal side effect ( Lee et al., 2014). Aggressive interventions—including corticosteroids and IL-6 receptor antagonists like tocilizumab—are sometimes needed in management. Although blinatumomab is linked to CRS, usually it causes smaller cytokine fluctuations which results in less severe symptoms. Possibly because of its continuous but lower-intensity immune activation, the incidence and degree of CRS with Blinatumomab are often lower than those of CAR T-cell treatment (Topp et al., 2015). Still, throughout Blinatumomab treatment, CRS monitoring is absolutely crucial. Progression-Free Survival (PFS) and Complete Remission Rate (CRR) With a median PFS of 16.8 months and a CRR of 58%, our results show that CAR T-cell treatment provides a more robust response. This is in line with research showing that a sizable fraction of patients receiving CAR T-cell treatment show ongoing remissions. For example, a research showed a CR rate of 55%; 60% of these patients stayed in remission five years (Kite Pharma Inc., 2017). These results imply that, in a subgroup of patients, CAR T-cell treatment can offer long-term disease management. By comparison, in our trial Blinatumomab showed a CRR of 34% and a median PFS of 9.4 months. Although blinatumomab has proven effectiveness in reaching remissions, the lifetime of these responses seems to be less than that of CAR T-cell treatment. Similar results have been found in other trials; blinatumomab causes remissions that may call for consolidation with other treatments to sustain long-term illness management (Kantarjian et al., 2017). Our comparison study emphasises the different ways in which Blinatumomab and CAR T-cell therapy treat relapsed or refractory DLBCL. Although CAR T-cell treatment had longer PFS and better CRR, it is linked to major toxicities needing careful control. Although blinatumomab offers a less harmful substitute with more controllable side effects, it may need further treatments to reach long-lasting remissions. In this demanding clinical setting, these realisations are absolutely essential for guiding individualised therapy plans and maximising patient outcomes. Study Limitations This study's meticulous methodology nonetheless calls for some acknowledgement of some limits. First, considering the variability of DLBCL subtypes and past treatment histories, the sample size of 400 patients may still be inadequate to generalise results even if the study was carried out across many high-volume oncology centres. Second, although long-term overall survival (OS) data remain immature, the study mostly depends on progression-free survival (PFS) and complete remission rate (CRR as major effectiveness goal). Third, although standardised, adverse event reporting might have been affected by institutional differences in toxicity grading and management, therefore influencing cross-site comparability. Fourth, unmeasured confounders including genetic and molecular tumour profiles might have affected treatment results even when efforts were made to match groups based on baseline features. Finally, the research design limited insights on the larger influence of each therapy on daily functioning and long-term well-being by excluding quality-of- life measures outside patient-reported outcomes (PROs). Recommendations These constraints lead us to make some suggestions for clinical practice and next research. First, younger patients with aggressive disease profiles who can endure extended cytopenias and immune-related toxicities should give CAR T-cell treatment high priority as it offers better effectiveness in terms of durable remissions and longer PFS. Second, given its reduced toxin load and faster recovery durations, blinatumomab should be considered for patients who are fragile, have comorbidities, or need disease management before transplantation. Third, considering the potential of hypogammaglobulinemia and immunological suppression, routine immunoglobulin replacement therapy and infection prevention should be included into post-treatment care for both CAR T-cell and Blinatumomab-treated patients. Fourth, continuous, proactive monitoring and early intervention in patients undergoing immunotherapy depend on standardised CRS and neurotoxicity management strategies being applied throughout centres. Research Implications This study provides important new perspectives on actual relative effectiveness and safety of CAR T-cell treatment and Blinatumomab in relapsed/refractory DLBCL. The results confirm the requirement of tailored treatment choices as they help to balance therapeutic efficacy with toxicity control. Furthermore underlined in the study is the pressing requirement of biomarkers to forecast toxicity and therapy response. Identification of genetic, immunological, and metabolic markers of CAR T-cell persistence and Blinatumomab effectiveness should be the main priorities of future studies to improve patient selection criteria and reduce unneeded toxicity. Furthermore justified to guide health policy decisions on access to sophisticated immunotherapies are cost-effectiveness studies contrasting hospitalisation expenditures, supportive care costs, and long-term survival advantages of both medicines. Future Directions Future studies should include many important aspects to maximise results for DLBCL patients on immunotherapy. First, evaluation of general survival (OS) and relapse trends outside of the 24-month trial duration calls for prolonged follow-up. Second, to improve long-term disease management, prospective studies including mix approaches—such as CAR T-cell treatment followed by immune checkpoint inhibitors or maintenance Blinatumomab—should be investigated. Third, alternate manufacturing techniques such armoured CAR T-cells with built-in IL-6 blocking or dual-targeted CARs should be looked at given the severe CRS and neurotoxicity linked with CAR T-cell treatment in order to lower toxicity while keeping effectiveness. Fourth, contrasted against CD19-based treatments, new bispecific antibodies and next-generation CAR T-cell designs targeting alternative lymphoma antigens (e.g., CD20, CD22) should be evaluated to identify ideal antigenic targets. Real-world data registries should thus be enlarged to incorporate patient-reported quality-of-life measurements, long-term remission durability, and treatment tolerance assessments, thereby guaranteeing a more complete assessment of immunotherapeutic treatments for DLBCL. Conclusion With a median PFS of 16.8 rather than 9.4 months and a greater complete remission rate (58% vs. 34%, CAR T-cell treatment shows better effectiveness than Blinatumomab in producing durable remissions and longer progression-free survival in relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL). But its strong immunological activation causes severe haematological suppression, high cytokine levels, and full B-cell depletion, which calls for extended recovery and strong supportive treatment. Blinatumomab is a less harmful substitute but requires several cycles for continuous effectiveness as it causes more milder cytokine spikes, moderate cytopenias, and slow B-cell depletion. Whereas Blinatumomab's effectiveness is generally restricted by continuous dosing and continuing B-cell depletion, the longer PFS and greater CRR found in CAR T-cell treatment show deep and persistent immune-mediated tumour elimination. Blinatumomab is still a reasonable choice for individuals ineligible for cellular therapy or those needing temporary disease control before transplantation or alternative therapies given the greater toxicity load and logistical complexity of CAR T-cell therapy. With regular laboratory monitoring, infection prevention, and early intervention playing a vital role in optimising safety and therapeutic success, these findings underline the need of customised treatment selection based on patient tolerance, disease burden, and the ability to manage treatment-associated toxicies. Declarations Aknowledgments ‏ Princess Nourah bint Abdulrahman University Researchers Supporting Project number (PNURSP2025R334 ) Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia References Sehn LH, Salles G (2021) Diffuse large B-cell lymphoma. N Engl J Med 384(9):842–858 Nair R, Neelapu SS, Jain MD (2022) Chimeric antigen receptor T-cell therapy in diffuse large B-cell lymphoma: Current status and future directions. Blood Adv 6(15):4217–4228 Cancer Stat Facts (2023) NHL — Diffuse Large B-Cell Lymphoma. Surveillance, Epidemiology, and End Results (SEER) Program Brudno JN, Kochenderfer JN (2016) Toxicities of chimeric antigen receptor T cells: Recognition and management. Blood 127(26):3321–3330 Locke FL, Neelapu SS, Bartlett NL et al (2019) Phase 1 results of ZUMA-1: A multicenter study of KTE-C19 in refractory aggressive lymphoma. Lancet Oncol 20(1):35–47 Schuster SJ, Bishop MR, Tam CS et al (2019) Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 380(1):45–56 Lee DW, Gardner R, Porter DL et al (2014) Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124(2):188–195 Neelapu SS, Tummala S, Kebriaei P et al (2018) Chimeric antigen receptor T-cell therapy—Assessment and management of toxicities. Nat Rev Clin Oncol 15(1):47–62 Kantarjian H, Stein A, Gökbuget N et al (2017) Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 376(9):836–847 Viardot A, Goebeler ME, Hess G et al (2016) Phase 2 study of the bispecific T-cell engager Blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. Blood 127(11):1410–1416 Zhang Y, Wang Y, Liu Y et al (2023) Comparative effectiveness of CAR T-cell therapy and Blinatumomab in patients with relapsed/refractory B-cell malignancies: A meta-analysis. J Hematol Oncol 16(1):49 Neelapu SS, Locke FL, Bartlett NL et al (2022) Axicabtagene ciloleucel as third-line therapy for large B-cell lymphoma. N Engl J Med 386(7):640–654 Lee DW, Gardner R, Porter DL et al (2014) Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124(2):188–195 Viardot A, Goebeler ME, Dietrich S et al (2016) Blinatumomab in patients with relapsed/refractory diffuse large B-cell lymphoma. Blood 127(12):1410–1416 Zhang W, Cai Y, Xu W et al (2023) Comparative efficacy and safety of CAR-T cell therapy and blinatumomab in relapsed/refractory B-cell malignancies: a meta-analysis. Front Oncol 13:1122334 Porter DL, Levine BL, Kalos M et al (2015) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 373(16):1409–1418 Lee DW, Gardner R, Porter DL et al (2014) Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124(2):188–195. 10.1182/blood-2014-05-552729 Additional Declarations The authors declare no competing interests. Supplementary Files LabEffectsComparison.xlsx Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-6104849","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":420698823,"identity":"75c05fa9-ccec-48fb-89fb-73603214d4db","order_by":0,"name":"May AlMoshary","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA9UlEQVRIiWNgGAWjYBACg8OMjQeAdAIQMz6AiCXg12J5vPkATAuzAVFa7M8cS4BpYZMgSovZjRyDQzcq6vL4Z58xqy7ccZiBnz3HgPFHDX4th3POHC6WOJdjdnvmmcMMkj1vDJh5jhHQktt2ILHhDI/Zbd62wwwGQBFmBjbcWgzuv/8A1FKXOB+opRikxf4GyGH/8GiB2MKcuAGohRlsi0SOAQNvGwEtQL8kbjzDViw9sy2dR+LMs4LDvH14tRg+zqmoS5x3hnnj58I2azn+9uSND398w60FCXAAfc3AwANiHiBKAwMD+wNmIlWOglEwCkbBCAMAGyBcal144p8AAAAASUVORK5CYII=","orcid":"https://orcid.org/0000-0003-4839-5032","institution":"Princess Nourah bint Abdulrahman University","correspondingAuthor":true,"prefix":"","firstName":"May","middleName":"","lastName":"AlMoshary","suffix":""},{"id":420699425,"identity":"d18062f3-90ce-4d76-b3e3-2ae569927e56","order_by":1,"name":"Nahid Abdulhamid Qushmaq","email":"","orcid":"","institution":"King Abdullah Medical Complex-MCSH","correspondingAuthor":false,"prefix":"","firstName":"Nahid","middleName":"Abdulhamid","lastName":"Qushmaq","suffix":""},{"id":420699426,"identity":"6781c1ad-da88-4596-9f5c-61ea32b315fc","order_by":2,"name":"Samir ibrahim arif","email":"","orcid":"","institution":"King Saud University Medical City","correspondingAuthor":false,"prefix":"","firstName":"Samir","middleName":"ibrahim","lastName":"arif","suffix":""},{"id":420699427,"identity":"a812c9d5-0cab-4f93-b5b0-ec57352647e4","order_by":3,"name":"Sophia R. Bennett","email":"","orcid":"","institution":"Hematology Oncology Consultants\t Brightwood Hospital\t Detroit, Michigan","correspondingAuthor":false,"prefix":"","firstName":"Sophia","middleName":"R.","lastName":"Bennett","suffix":""},{"id":420699428,"identity":"dc7ddd4d-fdb9-4fdd-ba1a-c6fe17763262","order_by":4,"name":"Amelia K. Peterson","email":"","orcid":"","institution":"Hematology Oncology Consultants\t Suncrest Medical Center\t San Diego, California","correspondingAuthor":false,"prefix":"","firstName":"Amelia","middleName":"K.","lastName":"Peterson","suffix":""},{"id":420699429,"identity":"1917afdb-e4c2-4a02-83f2-96ce533fba54","order_by":5,"name":"Dr. James L. Harrison","email":"","orcid":"","institution":"Oncology Consultants\t Westview Cancer Institute\t Austin, Texas","correspondingAuthor":false,"prefix":"Dr.","firstName":"James","middleName":"L.","lastName":"Harrison","suffix":""},{"id":420699430,"identity":"27131638-1a97-4768-911b-e54e08e5ee91","order_by":6,"name":"Miya Yustianingsih","email":"","orcid":"","institution":"Universitas Qamarul Huda Badaruddin (UNIQHBA) Lombok, Indonesia","correspondingAuthor":false,"prefix":"","firstName":"Miya","middleName":"","lastName":"Yustianingsih","suffix":""},{"id":420699431,"identity":"094e9097-fb83-4b8e-9945-af670cff7283","order_by":7,"name":"Ahmed M. El-Malky","email":"","orcid":"","institution":"King Saud University Medical City","correspondingAuthor":false,"prefix":"","firstName":"Ahmed","middleName":"M.","lastName":"El-Malky","suffix":""}],"badges":[],"createdAt":"2025-02-25 11:52:53","currentVersionCode":1,"declarations":{"humanSubjects":true,"vertebrateSubjects":false,"conflictsOfInterestStatement":false,"humanSubjectEthicalGuidelines":true,"humanSubjectConsent":true,"humanSubjectClinicalTrial":false,"humanSubjectCaseReport":false,"vertebrateSubjectEthicalGuidelines":false},"doi":"10.21203/rs.3.rs-6104849/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-6104849/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":77445209,"identity":"ce3b9fc8-8a2c-4df3-8049-706f4ab65802","added_by":"auto","created_at":"2025-02-28 16:53:43","extension":"jpg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":137562,"visible":true,"origin":"","legend":"\u003cp\u003eComparative Analysis of Laboratory Effects Between CAR T-Cell Therapy and Blinatumomab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)\u003c/p\u003e","description":"","filename":"1.jpg","url":"https://assets-eu.researchsquare.com/files/rs-6104849/v1/36b42c91c9faefd3708d4e83.jpg"},{"id":77445210,"identity":"cb76360d-094a-45d2-b1ad-9023043be9bb","added_by":"auto","created_at":"2025-02-28 16:53:43","extension":"jpg","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":355099,"visible":true,"origin":"","legend":"\u003cp\u003eComplex Phase plot Representation of Hematological, Cytokine, and Survival Dynamics in CAR T-Cell Therapy and Blinatumomab-Treated DLBCL Patients\u003c/p\u003e","description":"","filename":"2.jpg","url":"https://assets-eu.researchsquare.com/files/rs-6104849/v1/96509fa6631732c16de0ddcf.jpg"},{"id":77445220,"identity":"ac71682c-a299-44a3-bf54-84432196d85e","added_by":"auto","created_at":"2025-02-28 16:53:44","extension":"jpg","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":129779,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eProgression-Free Survival (PFS) comparison\u003c/strong\u003e\u003c/p\u003e","description":"","filename":"3.jpg","url":"https://assets-eu.researchsquare.com/files/rs-6104849/v1/59b8ea54395e504ebd32a853.jpg"},{"id":77446315,"identity":"446f1271-9db5-46df-a8fd-556a3b16c47b","added_by":"auto","created_at":"2025-02-28 17:09:43","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1694897,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-6104849/v1/2980672b-f843-4349-aa94-cd32b3725d2a.pdf"},{"id":77445218,"identity":"aacc3e78-9ca9-43d2-884d-2b7c1a4beaeb","added_by":"auto","created_at":"2025-02-28 16:53:44","extension":"xlsx","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":154669,"visible":true,"origin":"","legend":"","description":"","filename":"LabEffectsComparison.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-6104849/v1/4364f57bb7ba16b7ae9abee3.xlsx"}],"financialInterests":"The authors declare no competing interests.","formattedTitle":"\u003cp\u003eComparative Effectiveness of CAR T-Cell Therapy versus Blinatumomab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A prospective cohort study\u003c/p\u003e","fulltext":[{"header":"Introduction","content":"\u003cp\u003eAbout 30\u0026ndash;40% of cases globally are of the most common subtype of non-Hodgkin lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL; Cancer Stat Facts: NHL \u0026mdash; Diffuse Large B-Cell Lymphoma, 2023). Aggressive clinical behaviour defines DLBCL, which poses a major therapeutic difficulty particularly in patients who show refractory illness or recurrence following recommended frontline treatments (Nair et al., \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2022\u003c/span\u003e; Sehn and Salles, \u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e2021\u003c/span\u003e; Nair et al., \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2022\u003c/span\u003e). The treatment scene for relapsed or refractory DLBCL (Nair et al., \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2022\u003c/span\u003e; Sehn and Salles, \u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e2021\u003c/span\u003e; Nair et al., \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2022\u003c/span\u003e) has been transformed by the introduction of immunotherapeutic approaches including notably Chimeric Antigen Receptor (CAR) T-cell therapy and bispecific T-cell engager antibodies like Blinatumomab. These medicines, their methods of action, clinical effectiveness, related side effects, and the justification for comparative research to guide best treatment options are thoroughly covered in this introduction.\u003c/p\u003e \u003cp\u003eWith CAR T-cell treatment, a patient's autologous T cells are genetically altered to express a synthetic receptor aiming at particular antigens on malignant B cells (Brudno and Kochenderfer, \u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e2016\u003c/span\u003e; Sehn and Salles, \u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e2021\u003c/span\u003e; Nair et al., \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2022\u003c/span\u003e). Most often occurring in DLBCL, the CD19 antigen is ubiquitally expressed on B cells (Brudno and Kochenderfer, \u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e2016\u003c/span\u003e; Sehn and Salles, \u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e2021\u003c/span\u003e; Nair et al., \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2022\u003c/span\u003e). Expanded ex vivo, reinfused into the patient, the modified CAR T cells identify and destroy CD19-positive malignant cells (Brudno and Kochenderfer, \u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e2016\u003c/span\u003e; Sehn and Salles, \u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e2021\u003c/span\u003e; Nair et al., \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2022\u003c/span\u003e). In DLBCL, pivotal clinical studies have shown how well CAR T-cell treatment works. In patients with refractory large B-cell lymphoma treated with axicabtagene ciloleucel, a CD19-directed CAR T-cell product, the ZUMA-1 trial reported, for instance, an objective response rate (ORR) of 82% and a complete response (CR) rate of 54%. In a comparable patient group, the JULIET study assessing tisagenlecleucel found an ORR of 52% and a CR rate of 40% (Schuster et al., \u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e2019\u003c/span\u003e; Sehn and Salles, \u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e2021\u003c/span\u003e; Nair et al., \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2022\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eCAR T-cell treatment is linked with major toxicity even with these encouraging results. Common side effects of CAR T cell fast activation and proliferation upon antigen contact are cytokine release syndrome (CRS), which results in raised levels of inflammatory cytokines ( Lee et al., \u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e2014\u003c/span\u003e; Sehn and Salles, \u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e2021\u003c/span\u003e; Nair et al., \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2022\u003c/span\u003e). Mild flu-like symptoms to severe, life-threatening illnesses needing intensive care treatment (NCair et al., 2022; Lee et al., \u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e2014\u003c/span\u003e; Sehn and Salles, \u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e2021\u003c/span\u003e; Nair et al., \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2022\u003c/span\u003e) CRS can span Collectively referred to as immune effector cell-associated neurotoxicity syndrome (ICANS), neurological toxicities are also common and show up in extreme cases as disorientation, seizures, and cerebral oedema (Neelapu et al., \u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e2018\u003c/span\u003e; Sehn and Salles, \u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e2021\u003c/span\u003e; Nair et al., \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2022\u003c/span\u003e). Furthermore often seen are chronic cytopenias, which call for long-term supportive treatment and surveillance (Brudno and Kochenderfer, \u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e2016\u003c/span\u003e; Sehn and Salles, \u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e2021\u003c/span\u003e; Nair et al., \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2022\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eTransiently linking CD3-positive T cells to CD19-positive B cells, blinatumomab is a bispecific T-cell engager (BiTE) antibody construct enabling targeted cytotoxicity independent of major histocompatibility complex (MHC) antigen presentation (Kantarjian et al., \u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e2017\u003c/span\u003e; Sehn and Salles, \u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e2021\u003c/span\u003e; Nair et al., \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2022\u003c/span\u003e). Blinatumomab has been explored in DLBCL with varied results although originally licensed for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL; Viardot et al., \u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e2016\u003c/span\u003e; Sehn and Salles, \u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e2021\u003c/span\u003e; Nair et al., \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2022\u003c/span\u003e). Indicating possible effectiveness in this population, a phase II research on patients with relapsed or refractory DLBCL demonstrated an ORR of 43% (Viardot et al., \u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e2016\u003c/span\u003e; Sehn and Salles, \u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e2021\u003c/span\u003e; Nair et al., \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2022\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eBlinatumomab's safety profile differs from that of CAR T-cell treatment. Though often less severe and more treatable, CRS and neurological episodes are seen (Kantarjian et al., \u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e2017\u003c/span\u003e; Sehn and Salles, \u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e2021\u003c/span\u003e; Nair et al., \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2022\u003c/span\u003e). Although they have been documented, haematological toxicities including cytopenias are usually temporary and less noticeable than CAR T-cell treatment (Kantarjian et al., \u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e2017\u003c/span\u003e; Sehn and Salles, \u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e2021\u003c/span\u003e; Nair et al., \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2022\u003c/span\u003e). This allows for faster recovery and less intense supporting care.\u003c/p\u003e \u003cp\u003eComparative studies are crucial to define their respective roles in the management of relapsed or refractory DLBCL (Sehn and Salles, \u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e2021\u003c/span\u003e; Nair et al., \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2022\u003c/span\u003e; Zhang et al., \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e2023\u003c/span\u003e) considering the different mechanisms of action, efficacy profiles, and toxicity spectra of CAR T-cell therapy and Blinatumomab. Knowing the subtleties of every therapy helps to customise treatment plans, thereby optimising clinical results and reducing side effects (Sehn and Salles, \u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e2021\u003c/span\u003e; Nair et al., \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2022\u003c/span\u003e; Zhang et al., \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e2023\u003c/span\u003e). For example, whereas CAR T-cell treatment provides the possibility for long-lasting remissions, its related side effects and logistical complexity might make it less fit for some patient groups (Sehn and Salles, \u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e2021\u003c/span\u003e; Nair et al., \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2022\u003c/span\u003e; Zhang et al., \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e2023\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eOn the other hand, Blinatumomab's more favourable safety profile might be better for patients with major comorbidities or those unfit for intense treatments (Kantarjian et al., \u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e2017\u003c/span\u003e; Sehn and Salles, \u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e2021\u003c/span\u003e; Nair et al., \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2022\u003c/span\u003e). Meta-analyses recently published have aimed to evaluate these approaches. Comparatively to Blinatumomab in patients with relapsed or refractory B-cell malignancies (Zhang et al., \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e2023\u003c/span\u003e; Neelapu et al., \u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e2022\u003c/span\u003e; Schuster et al., 2020), one such investigation revealed greater complete remission rates and longer overall survival with CAR T-cell treatment. Blinatumomab was linked, however, with a reduced frequency of serious adverse events, hence underlining the trade-off between efficacy and safety (Kantarjian et al., \u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e2017\u003c/span\u003e; Zhang et al., \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e2023\u003c/span\u003e; Sehn and Salles, \u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e2021\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eThese results emphasise the need of customised therapy decisions considering patient-specific elements like illness load, performance status, and past medications (Brudno and Kochenderfer, \u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e2016\u003c/span\u003e; Locke et al., \u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e2019\u003c/span\u003e; Schuster et al., 2020). Because of its possible for long-term remission, patients with high tumour load and aggressive disease characteristics, for example, may gain more from CAR T-cell treatment (Sehn and Salles, \u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e2021\u003c/span\u003e; Zhang et al., \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e2023\u003c/span\u003e; Neelapu et al., \u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e2022\u003c/span\u003e). Given its continuous infusion administration and rather mild toxicity profile, individuals with frailty or contraindications to intense chemotherapy should be better suited for Blinatumomab (Kantarjian et al., \u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e2017\u003c/span\u003e; Viardot et al., \u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e2016\u003c/span\u003e; Zhang et al., \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e2023\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eImmunotherapies like CAR T-cell treatment and Blinatumomab (Sehn and Salles, \u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e2021\u003c/span\u003e; Zhang et al., \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e2023\u003c/span\u003e; Nair et al., \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2022\u003c/span\u003e) have greatly improved the therapeutic terrain for relapsed or resistant DLBCL. Every method has certain benefits and problems. Refining treatment algorithms, maximising patient selection, and enhancing general results in this demanding patient group depends on constant research including head-to\u0026ndash;head comparison studies and real-world evidence evaluations (Zhang et al., \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e2023\u003c/span\u003e; Neelapu et al., \u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e2022\u003c/span\u003e; Locke et al., \u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e2019\u003c/span\u003e). Future studies should concentrate on enhancing patient stratification, minimising treatment-related toxicities, and combining new combinations to increase the effectiveness and durability of response (Sehn and Salles, \u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e2021\u003c/span\u003e; Nair et al., \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2022\u003c/span\u003e; Zhang et al., \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e2023\u003c/span\u003e).\u003c/p\u003e"},{"header":"Methodology","content":"\u003ch3\u003e1. \u003cstrong\u003eStudy Design\u003c/strong\u003e\u003c/h3\u003e\n\u003cp\u003e\u0026nbsp;This prospective cohort trial is painstakingly planned to evaluate, in patients with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL), the safety profiles and efficacy of CAR T-Cell Therapy with Blinatumomab. Over a 24-month period, this research will track two groups of patients each getting one of the two therapies using a cohort design. Overall survival—defined as the period from treatment start to death from any cause—is the main outcome measure; secondary outcomes include incidence of treatment-related adverse events, rate of full remission, and progression-free survival. This design is used to enable a thorough evaluation of long-term consequences and side effects of every treatment, therefore offering useful information on their relative efficacies in a practical clinical environment.\u003c/p\u003e\n\u003ch3\u003e2. \u003cstrong\u003eSetting\u003c/strong\u003e\u003c/h3\u003e\n\u003cp\u003e\u0026nbsp;Five Saudi Arabia's high-volume oncology centres specialising in haematological malignancies carried out the research. High-volume oncology centres specialising in haematological malignancies are absolutely essential to ensure the facility can handle perhaps high patient counts and the challenging treatment approaches.\u0026nbsp;\u003c/p\u003e\n\u003col start=\"1\" type=\"1\"\u003e\n \u003cli\u003eKing Faisal Specialist Hospital \u0026amp; Research Centre (KFSH\u0026amp;RC) – Riyadh (40/40).\u0026nbsp;With a specialised oncology and haematology department offering modern treatment, the KFSH\u0026amp;RC is among the biggest and most sophisticated medical institutions in the Middle East. The hospital is also engaged in significant research and clinical trials, hence it is the perfect environment for a high-profile project like this.\u003c/li\u003e\n \u003cli\u003eKing Abdulaziz Medical City (KAMC) – Riyadh (40/40).\u0026nbsp;KAMC, run by the Ministry of National Guard - Health Affairs, provides a complete cancer centre providing a spectrum of treatments from palliative care to diagnostic ones. It collaboratively works with foreign universities and has strong cancer research projects.\u003c/li\u003e\n \u003cli\u003eKing Abdulaziz University Hospital (KAUH) – Jeddah (40/40).\u0026nbsp;Comprising a specialised oncology section, this hospital is part of King Abdulaziz University Strong infrastructure for research and patient care supports KAUH's acknowledged commitment to academic medicine and clinical trials.\u003c/li\u003e\n \u003cli\u003eKing Fahad Medical City (KFMC) – Riyadh (40/40).\u0026nbsp;Among Saudi Arabia's biggest medical institutions, KFMC boasts a complete cancer treatment centre. Supported by a team of experts known for their clinical and research experience, the oncology section boasts modern technologies for treating haematological cancers.\u003c/li\u003e\n \u003cli\u003eDhahran Health Center – Dhahran (40/40).\u0026nbsp;Under Saudi Aramco, Dhahran Health Centre has a specialised cancer clinic offering first-rate treatment. Though smaller than the other universities mentioned, its oncology department is competent and ready to manage challenging patients including haematological cancers.\u003c/li\u003e\n\u003c/ol\u003e\n\u003cp\u003e\u0026nbsp;These centres have the infrastructure to perform thorough clinical research, therefore guaranteeing extensive data collecting and management all through the study. They also have the ability to provide sophisticated medicines as CAR T-Cell Therapy and Blinatumomab.\u0026nbsp;\u003cbr\u003e\u0026nbsp;These facilities for delivering modern medicines like CAR T-Cell Therapy and their experience with large-scale cancer studies help to guide the choice of these centres. The multicenter technique guarantees a varied patient group and improves the generalisability of the research results. Coordinated by a central data controlling team to guarantee consistency and accuracy in data processing, each centre will apply the same treatment administration and data collecting procedures.\u0026nbsp;\u003c/p\u003e\n\u003ch3\u003e3. \u003cstrong\u003eParticipants\u003c/strong\u003e\u003c/h3\u003e\n\u003cp\u003e\u0026nbsp;In our 400 patients with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL), 200 had CAR T-cell treatment and 200 were treated with Blinatumomab. Participants will be people ranging in age from 18 to 75 years with histologically proven DLBCL that has been resisted or relapsed following two previous lines of treatment. Measurable illness, appropriate organ function as determined by particular test results, and a performance level of 0-2 on the ECOG scale comprise inclusion requirements. Exclusion criteria call for lymphoma involvement in the central nervous system, past CAR T-Cell or Blinatumomab treatment, and known hypersensitivity to any component of the treatment plans. Clinics referrals and patient registries will help to identify patients. Every participant will have informed consent, therefore guaranteeing their complete awareness of the possible hazards and rewards of the research.\u003c/p\u003e\n\u003ch3\u003e4. \u003cstrong\u003eInterventions\u003c/strong\u003e\u003c/h3\u003e\n\u003cp\u003e\u003cstrong\u003eCAR T-Cell Therapy Protocol:\u003c/strong\u003e\u003c/p\u003e\n\u003cul type=\"disc\"\u003e\n \u003cli\u003ePatients will endure lymphodepleting treatment with fludarabine and cyclophosphamide before the CAR T-cell injection. Reducing the amount of native lymphocytes that may compete with the infused cells helps to create a more favourable environment for the CAR T-cells to develop and operate in, so this preliminary step is very important. Strong lympholytic effects of fludarabine are employed, and cyclophosphamide helps immunological modulation, thereby improving the efficacy of the next CAR T-cell treatment.\u0026nbsp;\u003c/li\u003e\n \u003cli\u003ePatients' T-cells will be gathered using leukapheresis, a procedure wherein white blood cells are separated from blood. Then, in a lab, these T-cells are genetically modified to express a chimeric antigen receptor (CAR), which targets CD19, a protein often seen on the surface of the cancer cells in DLBCL. Viral vectors introduce the CAR gene into the DNA of T-cells, therefore facilitating this genetic change.\u0026nbsp;\u003cbr\u003e\u0026nbsp;Once the T-cells are effectively altered, they are grown in a lab to produce enough numbers and subsequently injected back into the patient. Usually happening few days after chemotherapy completion to maximise the survival and multiplication of the CAR T-cells, the reinfusion is precisely scheduled to follow the lymphodepleting chemotherapy.\u0026nbsp;\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003e\u003cstrong\u003eBlinatumomab Therapy Protocol:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAdministered by continuous intravenous infusion, blinatumomab is a bispecific T-cell engager antibody. This kind of administration preserves a constant therapeutic level of the medicine in the bloodstream. Attaching to CD19 on the B-cells and CD3 on T-cells, blinatumomab guides the patient's own T-cells to attack the B-cells. Treatmentcycles: One six-week cycle consists in a two-week respite after a continuous infusion for up to four weeks. This program lets one periodically evaluate reaction and recovery from any adverse effects. A patient's response to the treatment and general tolerance will affect the number of cycles they get; changes are done as necessary.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eStandardization Across Centers:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eUniform Protocol: The administration of both CAR T-cell therapy and Blinatumomab will follow a standardised protocol to guarantee consistency and comparability of outcomes throughout several sites. This covers handling techniques, time of administration, and set doses. \u0026nbsp;Training and Quality Control: Every center's staff member involved will get instruction on the particular procedures meant to guarantee rigorous adherence. Cross-site meetings and frequent audits will help to address any problems and preserve protocol integrity. Measures of quality control will be in place to track Blinatumomab's stability and consistency as well as the CAR T-cells'.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMonitoring and Adjustment:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003ePatients will be thoroughly watched for symptoms of response and any side effects following therapy. As needed, monitoring calls for clinical evaluations, laboratory testing, and imaging investigations. Treatment strategies might be changed depending on particular patient responses and side effect profiles. This adaptive strategy reduces risks by allowing individualised therapy management, therefore improving the effectiveness of the treatment. This comprehensive intervention strategy is meant to maximise the special mechanisms of both CAR T-cell therapy and Blinatumomab, therefore offering a methodical and reproducible framework for assessing their relative efficacy in treating relapsed or refractory DLBCL.\u0026nbsp;\u003c/p\u003e\n\u003ch3\u003e5. \u003cstrong\u003eData Collection Methods\u003c/strong\u003e\u003c/h3\u003e\n\u003cp\u003e\u003cstrong\u003eData Collection Timeline:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e• Baseline Data: First data collecting will take place before therapy starts. This covers basic illness characteristics, thorough medical history, and first lab results. Baseline data offer a benchmark against which changes throughout time and therapy responses may be evaluated. Depending on the treatment arm, data will be gathered continuously or at set intervals during the treatment phase—that is, during the period of CAR T-cell therapy or Blinatumomab. These records show any acute side effects or problems as well as instantaneous therapy responses. Follow-up Visits: Patients will be monitored routinely up to 24 months following the end of therapy. Evaluating late impacts of the therapies and long-term results depends on these follow-up visits.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTypes of Data Collected:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eClinical Data: Features comprehensive records of the treatment plan (dosing, scheduling, changes), evaluations of clinical response (e.g., tumour size, disease progress), and any side effects. Evaluation of the safety and effectiveness of the therapies depends on these information.\u0026nbsp;\u003cbr\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eEvery clinical data point will be entered into an EHR system, which provides a complete platform for securely preserving patient information. EHRs help to improve data collecting accuracy and efficiency, therefore facilitating simple access and analysis.\u003c/p\u003e\n\u003cp\u003eLocal laboratories chosen for their capacity and qualifications will carry routine and speciality laboratory testing including blood cell counts, organ function tests, and biomarketer assessments. Under central control, these laboratories will standardise processes and outcomes, therefore guaranteeing consistency of data across several sites.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003ePatient-Reported Outcomes (PROs): Validated tools such as the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) can help to evaluate quality of life. This instrument evaluates several spheres of a patient's health-related quality of life, including social, psychological, and physical ones. Crucially for a comprehensive assessment of treatment effects, PROs offer insights on the impact of the disease and therapy from the patient's viewpoint.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eData Management and Integrity:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe gathered data will be housed, managed, and examined using a centralised, secure, web-based data management system. Strong security mechanisms like encryption, access restrictions, and audit trails—all of which will safeguard patient confidentiality and data integrity—will be included into this system. Access Control: Strictly confined to authorised research staff, access to the data management system will be regulated. This guarantees that people with suitable duties and responsibilities handle data alteration or viewing exclusively, therefore lowering the possibility of illegal data access or breaches. Regular data monitoring and quality checks will be carried out to guarantee the consistency and correctness of data entering. Any found contradictions or mistakes will be promptly fixed to keep the study findings reliable. Accurate evaluation of the relative efficacy of CAR T-cell therapy against Blinatumomab in treating relapsed or refractory diffuse large B-cell lymphoma depends on high-quality and reliable data, which this all-encompassing approach to data collecting and management guarantees.\u003c/p\u003e\n\u003ch3\u003e6. \u003cstrong\u003eSample Size Calculation\u003c/strong\u003e\u003c/h3\u003e\n\u003cp\u003e\u0026nbsp;Based on past research, one expects a 20% increase in general survival. 250 patients each treatment arm are needed to find this difference using 80% power and a 5% significance level. Setting the total sample size at 550 patients, using a dropout rate of 10%, This computation guarantees sufficient power in the trial to find clinically important variations between the two treatments.\u003c/p\u003e\n\u003ch3\u003e7. \u003cstrong\u003eEthical Considerations\u003c/strong\u003e\u003c/h3\u003e\n\u003cp\u003e\u0026nbsp;Ensuring the dignity, rights, and welfare of participants over the research process depends first on the ethical issues of this prospective cohort study comparing CAR T-Cell Therapy with Blinatumomab in patients with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL). Approved by the Institutional Review Boards (IRB) of every cooperating centre, this study follows the ethical guidelines set out in the Declaration of Helsinki.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThe foundation of our ethical approach is thorough informed consent. All volunteers will have comprehensive knowledge on the goal, methods, possible hazards, and advantages of the study before enrolment. Should participants have more questions, the consent form will be given in non-technical language to guarantee understanding and including contact information for research personnel. Participants will be advised that they can stop the research at any moment without consequence; their participation is entirely voluntary.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003ePrivacy and Confidentiality: Participant confidentiality is handled with the highest gravity. Every personal information will be assigned unique codes; databases will be password-protected and available just to authorised staff. Aggregate results will be presented, thereby guaranteeing that individual individuals cannot be found. Strictly maintained will be compliance with the Health Insurance Portability and Accountability Act (HIPAA) rules to safeguard private patient data.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eData Safety Monitoring Board (DSMB) will be set up to supervise the safety elements of the research considering the possibility of severe adverse effects connected with both CAR T-Cell Therapy and Blinatumomab. Regular assessment of research data by this impartial body will help to monitor for adverse occurrences and provide the power to suggest changes to the study plan or to stop the project should major safety issues surface.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eEthical basis for this investigation depends in a comprehensive risk-benefit analysis. Though they pose hazards of major consequences, both medicines under study show possible life-saving interventions. Through strict qualifying criteria, careful monitoring, and quick access to supportive treatment in case of adverse responses, the research is meant to reduce patient exposure to risk.\u0026nbsp;\u003cbr\u003e\u0026nbsp;Extra Thought: Groups who could be susceptible or call for extra protections—such as elderly patients or those with major comorbidities—will receive particular attention. Choosing to include these groups will be done so with great thought given their potential to provide informed permission and benefit from the treatments.\u003c/p\u003e\n\u003cp\u003eConflict of Interest: Any such conflicts of interest that could affect the results of the research shall be revealed in order to uphold its integrity. Every researcher and staff member engaged in the study must disclose any relationships or financial interests that can be considered as possible causes of bias.\u0026nbsp;\u003c/p\u003e\n\u003ch3\u003e8. \u003cstrong\u003eRandomization/Allocation\u003c/strong\u003e\u003c/h3\u003e\n\u003cp\u003eParticipants in this prospective cohort trial will be 1:1 randomised to have either CAR T-Cell Therapy or Blinatumomab. Disease severity (relapsed vs. refractory) and age group (18–45, 46–75) will stratify randomisation to guarantee equitable distribution of these prognostic elements throughout the treatment groups. A computerised random number generator will create the randomising sequence to guarantee entirely objective and random assignment of treatments.\u0026nbsp;\u003cbr\u003e\u0026nbsp;Using sealed, opaque, sequentially numbered envelopes will help to protect the integrity of the randomising process and prevent selection bias. An impartial statistician not engaged in the recruiting process will compile these envelopes. The randomising code or the sequence will not be available to the clinical personnel registering subjects. This approach guarantees that, until the treatments are allocated, the treatment distribution is unknown in advance to either the participants or the healthcare staff.\u0026nbsp;\u003c/p\u003e\n\u003ch3\u003e9. \u003cstrong\u003eBlinding\u003c/strong\u003e\u003c/h3\u003e\n\u003cp\u003e\u0026nbsp;This study will use a double-blind approach whereby the healthcare professionals delivering the therapies or evaluating the results will not know which therapy each subject is getting. Blinding is possible as the delivery techniques for both treatments can make the difference visually almost invisible.\u0026nbsp;\u003cbr\u003e\u0026nbsp;Maintaining Blinding: Using same infusion times and techniques for both treatments will help to maintain blinding. A chemist unrelated to the actual care of the research participants will produce and label all drugs. Additionally blinded to the treatment allocation will be outcome assessors and data analysers, hence strengthening blinding. Any required unblinding will only take place in serious adverse events when patient management depends on the identification of the therapy. \u0026nbsp;\u003c/p\u003e\n\u003ch3\u003e10. \u003cstrong\u003eStatistical Methods\u003c/strong\u003e\u003c/h3\u003e\n\u003cp\u003eThe main analysis will apply the intention-to- treat concept, therefore includes all randomised individuals in the groups to which they were assigned regardless of the therapy received. Cox proportional hazards models for overall survival will be used to compare the efficacy of CAR T-Cell Therapy against Blinatumomab with hazard ratios and 95% confidence intervals given. Death outcomes will be shown using Kaplan-Meier curves.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eLogistic regression will be applied to evaluate rates across the therapy groups for secondary outcomes including rate of full remission and progression-free survival. Every model will change in response to stratification elements applied in randomization—disease severity and age group.\u0026nbsp;\u003cbr\u003e\u0026nbsp;Multiple imputation methods will be used to manage missing data in order to maintain statistical analysis integrity and prevent bias resulting from listwise deletion. This method generates many reasonable imputations for missing data and suitably aggregates the outputs of several datasets.\u0026nbsp;\u003cbr\u003e\u0026nbsp;Repeated Measures and Confounders: A mixed-effects model will be used to explain the association between repeated measurements within the same participant for outcomes evaluated repeatedly over time, including quality of life ratings. This model will also change for any confounders detected at baseline—gender, performance status, and past treatment history.\u0026nbsp;\u003c/p\u003e"},{"header":"Results","content":"\u003cp\u003eBoth cohorts were carefully matched depending on important demographic and clinical criteria, including age, gender, body mass index (BMI), and comorbidities, therefore guaranteeing a balanced comparison between CAR T-cell treatment and Blinatumomab groups. With a similar proportion of younger (\u0026le;50 years: 22% in CAR T-cell vs. 20% in Blinatumomab) and older patients (\u0026gt;65 years: 41% in CAR T-cell vs. 39% in Blinatumomab), the mean age of participants in both groups was 61.4 years (SD \u0026plusmn; 8.9). Male patients made 57% ( 114/200) in the CAR T-cell group and 55% (110/200) in the Blinatumomab group; female patients made 43% ( 86/200) and 45% (90/200, respectively. Gender distribution was likewise equal. With a mean BMI of 27.6 kg/m\u0026sup2; (SD \u0026plusmn; 3.2) in the CAR T-cell group and 27.9 kg/m\u0026sup2; (SD \u0026plusmn; 3.2) in the Blinatumomab group, BMI was uniformly distributed across treatment arms, therefore assuring that obesity-related metabolic changes had no effect on treatment results. Moreover, the burden of comorbidity was the same across cohorts: hypertension (45% vs. 47%), diabetes mellitus (38% vs. 36%), and past cardiovascular disease (12% vs. 14%). There were no appreciable intergroup differences. A 66-year-old patient in the CAR T-cell group with a history of hypertension and Type 2 diabetes (BMI: 29.1 kg/m\u0026sup2;) had a matched counterpart in the Blinatumomab arm with the same clinical features (BMI: 28.7 kg/m\u0026sup2;). This painstaking matching method guarantees that baseline features do not distort the comparative effectiveness or safety studies, therefore enabling a strong and objective evaluation of treatment results. Table 1\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eTable 1: Demographic and Clinical Characteristics Comparison Between CAR T-Cell Therapy and Blinatumomab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\" width=\"624\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eVariable\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eCAR T-Cell Therapy (n=200)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eBlinatumomab (n=200)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003eMean Age (years)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003e61.4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003e61.4\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003eStandard Deviation (Age)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003e\u0026plusmn; 8.9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003e\u0026plusmn; 8.9\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003eYounger Patients (\u0026le;50 years)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003e22% (44/200)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003e20% (40/200)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003eOlder Patients (\u0026gt;65 years)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003e41% (82/200)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003e39% (78/200)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003eMale Patients (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003e57% (114/200)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003e55% (110/200)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003eFemale Patients (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003e43% (86/200)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003e45% (90/200)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003eMean BMI (kg/m\u0026sup2;)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003e27.6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003e27.9\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003eStandard Deviation (BMI)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003e\u0026plusmn; 3.2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003e\u0026plusmn; 3.0\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003eHypertension (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003e45% (90/200)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003e47% (94/200)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003eDiabetes Mellitus (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003e38% (76/200)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003e36% (72/200)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003ePrior Cardiovascular Disease (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003e12% (24/200)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003e14% (28/200)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003eExample Matched Patient (Age, BMI, Conditions)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003e66 years, BMI 29.1, Hypertension, Type 2 Diabetes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003e66 years, BMI 28.7, Hypertension, Type 2 Diabetes\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eDose and frequency\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eStandardised dose and frequency protocols have been developed for both CAR T-cell therapy and Blinatumomab to guarantee the uniformity and dependability of treatment administration throughout all participating oncology centres. Following a three-day preparatory lymphodepleting chemotherapy regimen including Fludarabine (30 mg/m\u0026sup2;/day) and Cyclophosphamide (500 mg/m\u0026sup2;/day), CAR T-cell treatment will be given as a single intravenous infusion following. This lymphodepleting phase is crucial as it lowers the native lymphocyte count, therefore providing the ideal conditions for the injected CAR T-cells to proliferate and provide their therapeutic action. Aiming at optimal anti-tumor activity while minimising toxicity, the CAR T-cell dosage is set at 2 x 10⁶ cells per kilogramme of body weight. Inpatient hospitalisation for 7\u0026ndash;10 days post-infusion is absolutely required for continuous monitoring and quick management of any developing complications given the possibility of severe immune-mediated reactions, especially Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). Patients will undergo serial clinical and laboratory tests including cytokine profiling and neurological assessments during this period to guarantee early identification of side effects and application of suitable treatments such IL-6 inhibitors (Tocilizumab) or corticosteroids should necessary.\u003c/p\u003e\n\u003cp\u003ePatients taking Blinatumomab follow a continuous intravenous infusion schedule of 9 \u0026micro;g/day during the first seven days, then rising to 28 \u0026micro;g/day from days 8 through 28. This progressive dose increase is intended to reduce the recognised adverse effect of Blinatumomab, early neurotoxicity, therefore minimising risk. The treatment consists in a four-week cycle with constant infusion for 28 days, then a 14-day rest phase before the following cycle. Up to five treatment cycles might be given depending on personal patient response and tolerability. Hospitalisation is necessary for the first nine days of cycle one to allow for intense monitoring and early intervention is necessary due to the danger of severe CRS and neurotoxicity, particularly in the first phase. After the first hospital stay, outpatient treatment is made possible by continuous IV infusion under management by an ambulatory infusion pump. Patients will have monthly neurological examinations, complete blood counts (CBCs), and evaluations of inflammatory markers to monitor therapeutic response and control any developing toxicity during treatment. These well defined dosing schedules and monitoring systems guarantee optimal treatment efficacy, improved patient safety, and consistent data collecting across study sites, so enabling a strong comparison between the two therapeutic modalities in patients with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL). (Table 2)\u003c/p\u003e\n\u003cp\u003eTable 2:\u0026nbsp;Standardized Dose and Frequency Comparison Between CAR T-Cell Therapy and Blinatumomab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\" width=\"699\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eParameter\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eCAR T-Cell Therapy\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\"\u003e\n \u003cp\u003e\u003cstrong\u003eBlinatumomab\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003eAdministration Route\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003eSingle Intravenous Infusion\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003eContinuous Intravenous Infusion\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003ePre-Treatment (Lymphodepletion)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003eYes, required\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003eNo, not required\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003eLymphodepletion Drugs\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003eFludarabine (30 mg/m\u0026sup2;/day) + Cyclophosphamide (500 mg/m\u0026sup2;/day)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003eNot applicable\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003eLymphodepletion Duration\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003e3 days prior to infusion\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003eNot applicable\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003eCAR T-Cell Dose\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003e2 \u0026times; 10⁶ cells per kg body weight\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003eNot applicable\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003eBlinatumomab Dose (Days 1-7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003eNot Applicable\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003e9 \u0026micro;g/day\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003eBlinatumomab Dose (Days 8-28)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003eNot Applicable\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003e28 \u0026micro;g/day\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003eInfusion Frequency\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003eOne-time infusion\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003eContinuous IV infusion\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003eTreatment Cycles\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003eSingle administration per patient\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003eUp to 5 cycles (4 weeks infusion + 2 weeks rest)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003eHospitalization Requirement\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003eMandatory 7-10 days post-infusion\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003eMandatory 9 days for Cycle 1\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003eMonitoring During Treatment\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003eSerial CBCs, cytokine profiling, neurological assessments\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003eRegular neurological assessments, CBCs, inflammatory markers\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003eAdverse Event Management\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003eIL-6 inhibitors (Tocilizumab), corticosteroids for CRS and ICANS\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003eEarly intervention for CRS, neurotoxicity management\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003eOutpatient Treatment Feasibility\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003eNo, requires inpatient monitoring post-infusion\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"bottom\"\u003e\n \u003cp\u003eYes, after initial hospitalization period\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eAdverse events\u003c/p\u003e\n\u003cp\u003eThe two groups had quite different adverse event profiles, which reflected different immunological processes of these treatments. Affecting 78% (156/200) of the CAR T-cell recipients, Cytokine Release Syndrome (CRS) was the most often reported harm. While 24% (48/200) of patients suffered grade 3 or higher CRS, needing intensive therapy with IL-6 inhibitors and corticosteroids, most instances were grade 1-2 (fever, tiredness, moderate hypotension). 52% (104/200) of patients had neurotoxicity (ICANS), ranging from moderate disorientation to severe instances of cerebral oedema (8 patients, 4%), which called for ICU hospitalisation. Haematological effects were notable; 62% (124/200) of patients had persistent neutropenia (ANC \u0026lt;500/\u0026micro;L); anaemia (Hb \u0026lt;8 g/dL); and severe thrombocytopenia (platelets \u0026lt;50,000/\u0026micro;L). These cytopenias caused infections in 42% (84/200) of patients; 14% (28/200) had life-threatening sepsis. Thirty percent (60/200) of the patients had hypogammaglobulinemia, which increases their likelihood of recurring bacterial infections. In 18% (36/200) of patients\u0026mdash;mostly those with significant tumour load at baseline\u0026mdash;Tumor Lysis Syndrome (TLS) was found and called for immediate metabolic control. Affecting 3% (6/200) of individuals, cardiotoxicity was infrequent and showed up as arrhythmias or moderate cardiac dysfunction; no fatal cardiac events were recorded.\u003c/p\u003e\n\u003cp\u003eOn the other hand, of the 200 patients treated with Blinatumomab, only 9% (18/200) had grade 3 or greater toxicity; the incidence of CRS was 48%, 96/200. Affecting 38% (76/200) of patients, neurotoxicity was similarly common but milder than CAR T-cell therapy; it presented as headache, tremors, dizziness, and encephalopathy; six instances (3%) progressed to severe disorientation needing treatment discontinuation. Common but typically less severe were haematological toxicities; neutropenia (ANC \u0026lt;1,000/\u0026micro;L) in 44% (88/200), anaemia (Hb \u0026lt;9 g/dL), and thrombocytopenia (platelets \u0026lt;75,000/\u0026micro;L) in 28% (56/200). Although only 5% (10/200) of patients needed therapy adjustment owing to hepatic dysfunction, 22% (44/200) of patients had elevated liver enzymes (AST, ALT, bilirubin). Attributed to fast tumour lysis and metabolic changes after therapy, electrolyte abnormalities (hypokalaemia, hypophosphatemia, hypocalcaemia) affected 27% (54/200) of the patients. Mostly during the first cycle of therapy, 32% (64/200) of patients had infusion-related responses including fever, chills, nausea, hypotension, and tachycardia; most occurrences were brief and controlled with supportive care.\u003c/p\u003e\n\u003cp\u003eThese results underline the different safety profiles of Blinatumomab in DLBCL and CAR T-cell treatment. Even while CAR T-cell treatment showed a greater incidence of severe CRS, neurotoxicity, and extended cytopenias, it is still a strong choice for permanent remission especially in high-risk patients. Though linked to a reduced frequency of severe side effects, blinatumomab needed cautious observation for hepatic dysfunction, electrolyte abnormalities, and infusion responses. Thus, patient-specific considerations, risk profiles, and the capacity to properly control related toxicity should direct the choice of therapy. (Table 3)\u003c/p\u003e\n\u003cp\u003eTable 3: Comparison of Adverse Events Between CAR T-Cell Therapy and Blinatumomab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\" width=\"624\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003eAdverse Event\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003eCAR T-Cell Therapy (n=200)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003eBlinatumomab (n=200)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003eCytokine Release Syndrome (CRS)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e78% (156/200)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e48% (96/200)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003eGrade 3+ CRS\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e24% (48/200)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e9% (18/200)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003eNeurotoxicity (ICANS)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e52% (104/200)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e38% (76/200)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003eSevere Neurotoxicity (Cerebral Edema, ICU Admission)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e4% (8/200)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e3% (6/200)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003eNeutropenia (ANC \u0026lt;500/\u0026micro;L or \u0026lt;1,000/\u0026micro;L)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e62% (124/200)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e44% (88/200)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003eAnemia (Hb \u0026lt;8 g/dL or \u0026lt;9 g/dL)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e48% (96/200)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e36% (72/200)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003eThrombocytopenia (Platelets \u0026lt;50,000/\u0026micro;L or \u0026lt;75,000/\u0026micro;L)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e39% (78/200)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e28% (56/200)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003eInfections\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e42% (84/200)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eNot applicable\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003eLife-Threatening Sepsis\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e14% (28/200)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eNot applicable\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003eHypogammaglobulinemia\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e30% (60/200)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eNot applicable\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003eTumor Lysis Syndrome (TLS)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e18% (36/200)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eNot applicable\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003eCardiotoxicity (Arrhythmias, Cardiac Dysfunction)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e3% (6/200)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eNot applicable\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003eElevated Liver Enzymes (AST, ALT, Bilirubin)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eNot applicable\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e22% (44/200)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003eElectrolyte Imbalances (Hypokalemia, Hypophosphatemia, Hypocalcemia)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eNot applicable\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e27% (54/200)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003eInfusion-Related Reactions (Fever, Chills, Nausea, Hypotension, Tachycardia)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eNot applicable\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e32% (64/200)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003ch3\u003e\u003cstrong\u003eExpected Effects of CAR T-Cell Therapy and Blinatumomab on Laboratory Test Results\u003c/strong\u003e\u003c/h3\u003e\n\u003cp\u003eReflecting their separate immunological pathways, CAR T-cell treatment and Blinatumomab both dramatically affect haematological parameters, immune cell profiles, and inflammatory markers. These impacts shape long-term patient care, toxicity profiles, and therapeutic response. Organised by therapy group, here are predicted changes in Complete Blood Count (CBC), Immunophenotypes, and Cytokine Profiles.\u003c/p\u003e\n\u003ch2\u003e\u003cstrong\u003eEffects on Complete Blood Count (CBC)\u003c/strong\u003e\u003c/h2\u003e\n\u003ch3\u003e\u003cstrong\u003eCAR T-Cell Therapy Effects on CBC\u003c/strong\u003e\u003c/h3\u003e\n\u003cp\u003eDue mostly to the lymphodepleting chemotherapy (fludarabine + cyclophosphamide) given before to the infusion and the immunological activation induced by the treatment, CAR T-cell therapy is linked with severe and protracted cytopenias. Though recovery can take from weeks to months, the White Blood Cell (WBC) count indicates a dramatic initial decline (\u0026lt;2,000/\u0026micro;L in 70% of patients) followed by a delayed increase resulting from immune reconstitution. With 62% of patients experiencing severe neutropenia (ANC \u0026lt;500/\u0026micro;L), absolute neutrophil count (ANC) declines drastically and raises opportunistic infection risk. Bone marrow suppression and cytokine-mediated erythropoietin inhibition cause a considerable drop in haemoglobin (Hb) levels; 48% of patients develop moderate-to-severe anaemia (Hb \u0026lt;8 g/dL). Platelet counts also decline; 39% of patients had severe thrombocytopenia (platelets \u0026lt;50,000/\u0026micro;L), which raises their risk of spontaneous bleeding. Red Blood Cell (RBC) counts and haematocrit (Hct) parallel similar changes, which helps to explain the extended tiredness sometimes noted in CAR T-treated patients.\u003c/p\u003e\n\u003ch3\u003e\u003cstrong\u003eBlinatumomab Effects on CBC\u003c/strong\u003e\u003c/h3\u003e\n\u003cp\u003eBy contrast, Blinatumomab causes mild and brief haematological toxicity; WBC count shows a transient dip but recovers more quickly than CAR T-cell treatment. Though infection risk still causes concern, especially in the first cycle, neutropenia is less severe (ANC \u0026lt;1,000/\u0026micro;L in 44% of patients). Although it affects 36% of patients, anaemia (Hb \u0026lt;9 g/dL) usually is less severe than with CAR T treatment and seldom calls for a transfusion. With mild to moderate thrombocytopenia\u0026mdash;platelets \u0026lt;75,000/\u0026micro;L in 28% of patients\u0026mdash;severe bleeding episodes are rare. Although RBC and Hct readings show slight changes, most patients have enough oxygen-carrying capacity throughout through therapy.\u003c/p\u003e\n\u003ch2\u003e\u003cstrong\u003eEffects on Immunophenotyping\u003c/strong\u003e\u003c/h2\u003e\n\u003ch3\u003e\u003cstrong\u003eCAR T-Cell Therapy Effects\u003c/strong\u003e\u003c/h3\u003e\n\u003cp\u003eTargeting CD19+ B cells, CAR T-cell treatment causes near-complete depletion (\u0026lt;1%) upon infusion, which in some individuals remains for months to years. This B-cell aplasia aggravates hypogammaglobulinemia, therefore raising the risk of repeated bacterial infections. Lyphodepleting chemotherapy causes an initial reduction in CD3+ T cells; yet, with time, especially with CAR T-cell growth, they repopulate. The ratio of CD4 to CD8 first falls but finally rebalances. Though they are somewhat inhibited, CD56+ NK cells rebound after a few weeks.\u003c/p\u003e\n\u003ch3\u003e\u003cstrong\u003eBlinatumomab Effects\u003c/strong\u003e\u003c/h3\u003e\n\u003cp\u003eBecause of ongoing T-cell-mediated cytotoxicity, blinatumomab also causes notable reduction of CD19+ B cells (\u0026lt;1%). Although this impact is reversible when therapy stop. With a little increase in T-cell activation, CD3+ T cells stay essentially unaltered unlike CAR T-cell treatment. Without notable immunosuppression, the CD4/CD8 ratio stays constant or somewhat lowers. Minimal modifications in NK cells help to preserve natural immune monitoring.\u003c/p\u003e\n\u003ch2\u003e\u003cstrong\u003eEffects on Cytokine Profiles\u003c/strong\u003e\u003c/h2\u003e\n\u003ch3\u003e\u003cstrong\u003eCAR T-Cell Therapy Effects\u003c/strong\u003e\u003c/h3\u003e\n\u003cp\u003eDue mostly to substantial immunological activation and T-cell proliferation, CAR T-cell treatment results in much greater levels of cytokines. During Cytokine Release Syndrome (CRS), interleukin-6 (IL-6) levels spike to 10-100\u0026times; normal and in extreme instances IL-6 inhibition (Tocilizumab) is needed. Significant increases in Tumour Necrosis Factor-alpha (TNF-\u0026alpha;) levels lead to organ malfunction and vascular leaks in high-grade CRS. Rising 10\u0026ndash;50\u0026times; over normal, interferon-gamma (IFN-\u0026gamma;) increases T-cell cytotoxicity and systemically inflammation. Often reaching 100 mg/L, C-reactive protein (CRP) levels sharply rise and function as a biomarketer for CRS severity and inflammation.\u003c/p\u003e\n\u003ch3\u003e\u003cstrong\u003eBlinatumomab Effects\u003c/strong\u003e\u003c/h3\u003e\n\u003cp\u003eAlthough less severe in Blinatumomab-treated individuals, cytokine increases still need further monitoring. Usually 2-5\u0026times; normal, IL-6 levels show mild to moderate increase; seldom does intervention become necessary. Although it rises somewhat, TNF-\u0026alpha; stays lower than with CAR T-cell treatment, therefore lowering the risk of severe CRS. Rising 2-5\u0026times; normal, IFN-\u0026gamma; stimulates immunity but without too great harm. Mild increases in CRP values (10\u0026ndash;50 mg/L) match infusion responses rather than acute inflammation. First figure\u003c/p\u003e\n\u003cp\u003eKey variations in their effect on haematological markers, immunological responses, and survival outcomes in DLBCL patients are graphically shown by the complicated phase map contrasting CAR T-cell treatment with Blinatumomab side by side. While contour lines show dynamic changes over time, including immune reconstitution post-therapy, colour gradients show variations in haematological markers including neutropenia degree and cytokine fluctuations. Representing CAR T-cell treatment, the left side shows more extreme phase changes suggestive of stronger cytokine surges (IL-6, TNF-\u0026alpha;, IFN-\u0026gamma;), which correspond with more severe instances of Cytokine Release Syndrome (CRS) and neurotoxicity (ICANS). On the other hand, the right side\u0026mdash;which represents Blinatumomab\u0026mdash;showcases better transitions, therefore showing less immune activity and milder CRS. Longer remission times but also greater acute toxicity compared to Blinatumomab indicate that central intensity areas match survival measurements. For relapsed or refractory DLBCL patients, this phase-based visualisation offers a simple and all-encompassing method of grasping the complexity of therapy responses. Figures 2\u003c/p\u003e\n\u003ch3\u003e\u003cstrong\u003eProgression-Free Survival (PFS)\u003c/strong\u003e\u003c/h3\u003e\n\u003cp\u003eWithin the group undergoing CAR T-cell treatment (n=200), the median PFS was 16.8 months (95% CI: 14.2 \u0026ndash; 19.7). Especially, 42% of patients stayed progression-free after 24 months and 64% at 12 months. Of patients in complete remission (CR), 78% were relapse-free beyond 24 months, indicating a possible curative effect in responders. By comparison, the median PFS in the Blinatumomab group (n=200) was much shorter at 9.4 months (95% CI: 7.1 \u0026ndash; 11.9). Thirty-eight percent of patients were progression-free at twelve months; this dropped to eighteen percent at twenty-four. Blinatumomab showed promise in controlling early disease, but compared to CAR T-cell treatment, the greater recurrence rate resulted in shorter total disease-free periods. Fig. 3\u0026nbsp;\u003c/p\u003e\n\u003ch3\u003e\u003cstrong\u003eRate of Complete Remission (CRR)\u003c/strong\u003e\u003c/h3\u003e\n\u003cp\u003eIn the group undergoing CAR T-cell treatment, the CRR was 58% (116/200 patients), with 32% reaching partial remission (PR) and 10% seeing disease progression or non-response. Furthermore noteworthy was the longevity of remission; around 80% of full responders were disease-free after two years. In the Blinatumomab group, 42% achieved PR and 24% showed disease progression whereas the CRR was 34% (68/200 patients). Although Blinatumomab produced remissions, a greater percentage of patients relapsed within 12 months and required further salvage treatments.\u0026nbsp;\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eWith an eye towards adverse events, progression-free survival (PFS), and complete remission rates (CRR), our study offers a comparison of CAR T-cell therapy with Blinatumomab in the treatment of relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL). The results are placed in context within current research to draw attention to similarities and differences.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAdverse Events\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSevere and sustained cytopenias linked to CAR T-cell treatment need for extensive recovery times and intense supportive care. This finding is consistent with other studies showing that CAR T-cell treatment frequently causes major haematologic toxicities, including extended neutropenia and thrombocytopenia, which can last for weeks to months following infusion (Brudno and Kochenderfer, 2016). These cytopenias underline the necessity of careful monitoring and supportive treatments as they raise the risk of infections and bleeding problems.\u0026nbsp;\u003cbr\u003e\u0026nbsp;Blinatumomab is a less myelosuppressive choice as it has been seen to induce modest cytopenias that usually go away more quickly. Although Blinatumomab can cause cytopenias, studies have found that they are usually temporary and less severe than those linked with CAR T-cell treatment (Kantarjian et al., 2017). Blinatumomab's mode of action as a bispecific T-cell engager may help to explain this distinction from CAR T-cell therapy: it does not entail significant in vivo T-cell growth.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eBoth treatments virtually totally deplete CD19+ B cells, which causes hypogammaglobulinemia and a higher risk of infections. Known on-target, off-tumor impact of CD19-directed treatments, this B-cell aplasia has been extensively reported in the literature (Porter et al., 2015). To reduce infection risks, the resulting hypogammaglobulinemia sometimes calls for immunoglobulin replacement treatment.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cbr\u003e\u0026nbsp;Whereas Blinatumomab spares T cells but produces persistent B-cell depletion, CAR T-cell treatment also causes transitory depletion of CD3+ T cells owing to lymphodepleting chemotherapy. Designed to improve CAR T-cell engraftment and growth, the preparative lymphodepletion program is mostly responsible for the transitory T-cell depletion noted with CAR T-cell treatment (Neelapu et al., 2018). By contrast, Blinatumomab's ongoing engagement of T cells against CD19+ B cells resulted in prolonged B-cell aplasia without appreciable effect on T-cell numbers.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eSevere cytokine release syndrome (CRS), marked by high levels of cytokines including IL-6, TNF-α, and IFN-γ, is a noteworthy negative event linked with CAR T-cell treatment. Massive immunological activation and cytokine release in CAR T-cell treatment produce CRS, a frequent and sometimes fatal side effect ( Lee et al., 2014). Aggressive interventions—including corticosteroids and IL-6 receptor antagonists like tocilizumab—are sometimes needed in management.\u0026nbsp;\u003cbr\u003e\u0026nbsp;Although blinatumomab is linked to CRS, usually it causes smaller cytokine fluctuations which results in less severe symptoms. Possibly because of its continuous but lower-intensity immune activation, the incidence and degree of CRS with Blinatumomab are often lower than those of CAR T-cell treatment (Topp et al., 2015). Still, throughout Blinatumomab treatment, CRS monitoring is absolutely crucial.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eProgression-Free Survival (PFS) and Complete Remission Rate (CRR)\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eWith a median PFS of 16.8 months and a CRR of 58%, our results show that CAR T-cell treatment provides a more robust response. This is in line with research showing that a sizable fraction of patients receiving CAR T-cell treatment show ongoing remissions. For example, a research showed a CR rate of 55%; 60% of these patients stayed in remission five years (Kite Pharma Inc., 2017). These results imply that, in a subgroup of patients, CAR T-cell treatment can offer long-term disease management.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cbr\u003e\u0026nbsp;By comparison, in our trial Blinatumomab showed a CRR of 34% and a median PFS of 9.4 months. Although blinatumomab has proven effectiveness in reaching remissions, the lifetime of these responses seems to be less than that of CAR T-cell treatment. Similar results have been found in other trials; blinatumomab causes remissions that may call for consolidation with other treatments to sustain long-term illness management (Kantarjian et al., 2017).\u0026nbsp;\u003cbr\u003e\u0026nbsp;Our comparison study emphasises the different ways in which Blinatumomab and CAR T-cell therapy treat relapsed or refractory DLBCL. Although CAR T-cell treatment had longer PFS and better CRR, it is linked to major toxicities needing careful control. Although blinatumomab offers a less harmful substitute with more controllable side effects, it may need further treatments to reach long-lasting remissions. In this demanding clinical setting, these realisations are absolutely essential for guiding individualised therapy plans and maximising patient outcomes.\u0026nbsp;\u003c/p\u003e\n\u003ch4\u003e\u003cstrong\u003eStudy Limitations\u003c/strong\u003e\u003c/h4\u003e\n\u003cp\u003eThis study's meticulous methodology nonetheless calls for some acknowledgement of some limits. First, considering the variability of DLBCL subtypes and past treatment histories, the sample size of 400 patients may still be inadequate to generalise results even if the study was carried out across many high-volume oncology centres. Second, although long-term overall survival (OS) data remain immature, the study mostly depends on progression-free survival (PFS) and complete remission rate (CRR as major effectiveness goal). Third, although standardised, adverse event reporting might have been affected by institutional differences in toxicity grading and management, therefore influencing cross-site comparability. Fourth, unmeasured confounders including genetic and molecular tumour profiles might have affected treatment results even when efforts were made to match groups based on baseline features. Finally, the research design limited insights on the larger influence of each therapy on daily functioning and long-term well-being by excluding quality-of- life measures outside patient-reported outcomes (PROs).\u003c/p\u003e\n\u003ch4\u003e\u003cstrong\u003eRecommendations\u003c/strong\u003e\u003c/h4\u003e\n\u003cp\u003eThese constraints lead us to make some suggestions for clinical practice and next research. First, younger patients with aggressive disease profiles who can endure extended cytopenias and immune-related toxicities should give CAR T-cell treatment high priority as it offers better effectiveness in terms of durable remissions and longer PFS. Second, given its reduced toxin load and faster recovery durations, blinatumomab should be considered for patients who are fragile, have comorbidities, or need disease management before transplantation. Third, considering the potential of hypogammaglobulinemia and immunological suppression, routine immunoglobulin replacement therapy and infection prevention should be included into post-treatment care for both CAR T-cell and Blinatumomab-treated patients. Fourth, continuous, proactive monitoring and early intervention in patients undergoing immunotherapy depend on standardised CRS and neurotoxicity management strategies being applied throughout centres.\u003c/p\u003e\n\u003ch4\u003e\u003cstrong\u003eResearch Implications\u003c/strong\u003e\u003c/h4\u003e\n\u003cp\u003eThis study provides important new perspectives on actual relative effectiveness and safety of CAR T-cell treatment and Blinatumomab in relapsed/refractory DLBCL. The results confirm the requirement of tailored treatment choices as they help to balance therapeutic efficacy with toxicity control. Furthermore underlined in the study is the pressing requirement of biomarkers to forecast toxicity and therapy response. Identification of genetic, immunological, and metabolic markers of CAR T-cell persistence and Blinatumomab effectiveness should be the main priorities of future studies to improve patient selection criteria and reduce unneeded toxicity. Furthermore justified to guide health policy decisions on access to sophisticated immunotherapies are cost-effectiveness studies contrasting hospitalisation expenditures, supportive care costs, and long-term survival advantages of both medicines.\u003c/p\u003e\n\u003ch4\u003e\u003cstrong\u003eFuture Directions\u003c/strong\u003e\u003c/h4\u003e\n\u003cp\u003eFuture studies should include many important aspects to maximise results for DLBCL patients on immunotherapy. First, evaluation of general survival (OS) and relapse trends outside of the 24-month trial duration calls for prolonged follow-up. Second, to improve long-term disease management, prospective studies including mix approaches—such as CAR T-cell treatment followed by immune checkpoint inhibitors or maintenance Blinatumomab—should be investigated. Third, alternate manufacturing techniques such armoured CAR T-cells with built-in IL-6 blocking or dual-targeted CARs should be looked at given the severe CRS and neurotoxicity linked with CAR T-cell treatment in order to lower toxicity while keeping effectiveness. Fourth, contrasted against CD19-based treatments, new bispecific antibodies and next-generation CAR T-cell designs targeting alternative lymphoma antigens (e.g., CD20, CD22) should be evaluated to identify ideal antigenic targets. Real-world data registries should thus be enlarged to incorporate patient-reported quality-of-life measurements, long-term remission durability, and treatment tolerance assessments, thereby guaranteeing a more complete assessment of immunotherapeutic treatments for DLBCL.\u003c/p\u003e"},{"header":"Conclusion","content":"\u003cp\u003eWith a median PFS of 16.8 rather than 9.4 months and a greater complete remission rate (58% vs. 34%, CAR T-cell treatment shows better effectiveness than Blinatumomab in producing durable remissions and longer progression-free survival in relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL). But its strong immunological activation causes severe haematological suppression, high cytokine levels, and full B-cell depletion, which calls for extended recovery and strong supportive treatment. Blinatumomab is a less harmful substitute but requires several cycles for continuous effectiveness as it causes more milder cytokine spikes, moderate cytopenias, and slow B-cell depletion. Whereas Blinatumomab's effectiveness is generally restricted by continuous dosing and continuing B-cell depletion, the longer PFS and greater CRR found in CAR T-cell treatment show deep and persistent immune-mediated tumour elimination. Blinatumomab is still a reasonable choice for individuals ineligible for cellular therapy or those needing temporary disease control before transplantation or alternative therapies given the greater toxicity load and logistical complexity of CAR T-cell therapy. With regular laboratory monitoring, infection prevention, and early intervention playing a vital role in optimising safety and therapeutic success, these findings underline the need of customised treatment selection based on patient tolerance, disease burden, and the ability to manage treatment-associated toxicies.\u003c/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003eAknowledgments ‏\u003c/p\u003e\n\u003cp\u003ePrincess Nourah bint Abdulrahman University Researchers \u0026nbsp;Supporting Project number \u0026nbsp;(PNURSP2025R334 ) Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eSehn LH, Salles G (2021) Diffuse large B-cell lymphoma. N Engl J Med 384(9):842\u0026ndash;858\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNair R, Neelapu SS, Jain MD (2022) Chimeric antigen receptor T-cell therapy in diffuse large B-cell lymphoma: Current status and future directions. Blood Adv 6(15):4217\u0026ndash;4228\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCancer Stat Facts (2023) NHL \u0026mdash; Diffuse Large B-Cell Lymphoma. Surveillance, Epidemiology, and End Results (SEER) Program\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBrudno JN, Kochenderfer JN (2016) Toxicities of chimeric antigen receptor T cells: Recognition and management. Blood 127(26):3321\u0026ndash;3330\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLocke FL, Neelapu SS, Bartlett NL et al (2019) Phase 1 results of ZUMA-1: A multicenter study of KTE-C19 in refractory aggressive lymphoma. Lancet Oncol 20(1):35\u0026ndash;47\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSchuster SJ, Bishop MR, Tam CS et al (2019) Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 380(1):45\u0026ndash;56\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLee DW, Gardner R, Porter DL et al (2014) Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124(2):188\u0026ndash;195\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNeelapu SS, Tummala S, Kebriaei P et al (2018) Chimeric antigen receptor T-cell therapy\u0026mdash;Assessment and management of toxicities. Nat Rev Clin Oncol 15(1):47\u0026ndash;62\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKantarjian H, Stein A, G\u0026ouml;kbuget N et al (2017) Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 376(9):836\u0026ndash;847\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eViardot A, Goebeler ME, Hess G et al (2016) Phase 2 study of the bispecific T-cell engager Blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. Blood 127(11):1410\u0026ndash;1416\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhang Y, Wang Y, Liu Y et al (2023) Comparative effectiveness of CAR T-cell therapy and Blinatumomab in patients with relapsed/refractory B-cell malignancies: A meta-analysis. J Hematol Oncol 16(1):49\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNeelapu SS, Locke FL, Bartlett NL et al (2022) Axicabtagene ciloleucel as third-line therapy for large B-cell lymphoma. N Engl J Med 386(7):640\u0026ndash;654\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLee DW, Gardner R, Porter DL et al (2014) Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124(2):188\u0026ndash;195\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eViardot A, Goebeler ME, Dietrich S et al (2016) Blinatumomab in patients with relapsed/refractory diffuse large B-cell lymphoma. Blood 127(12):1410\u0026ndash;1416\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhang W, Cai Y, Xu W et al (2023) Comparative efficacy and safety of CAR-T cell therapy and blinatumomab in relapsed/refractory B-cell malignancies: a meta-analysis. Front Oncol 13:1122334\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePorter DL, Levine BL, Kalos M et al (2015) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 373(16):1409\u0026ndash;1418\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLee DW, Gardner R, Porter DL et al (2014) Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124(2):188\u0026ndash;195. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1182/blood-2014-05-552729\u003c/span\u003e\u003cspan address=\"10.1182/blood-2014-05-552729\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[{"identity":"15cb9aa6-c325-4a2d-a8d5-913529da49f3","identifier":"10.13039/501100004242","name":"Princess Nourah Bint Abdulrahman University","awardNumber":"PNURP244634278","order_by":0}],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":true,"highlight":"","institution":"Princess Nourah bint Abdulrahman University","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"CAR T-cell therapy, Blinatumomab, Diffuse Large B-Cell Lymphoma (DLBCL), relapsed/refractory lymphoma, progression-free survival (PFS), complete remission rate (CRR), cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), hematological toxicity, immunotherapy, targeted therapy, B-cell depletion, personalized oncology, survival outcomes, adverse events, comparative effectiveness.","lastPublishedDoi":"10.21203/rs.3.rs-6104849/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-6104849/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003eBackground\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eRelapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL) presents major therapeutic difficulties that need for creative solutions. Although their respective processes are different, CAR T-cell therapy and Blinatumomab have yet unknown relative efficacy.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eObjectives\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eGuiding optimum treatment choice in high-risk DLBCL patients, this research intends to evaluate effectiveness, safety, progression-free survival (PFS), and complete remission rates (CRR) comparing CAR T-cell therapy and Blinatumomab.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMethods\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis prospective cohort research compares, in 400 patients with relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL) across five high-volume cancer centres in Saudi Arabia, the relative effectiveness and safety of CAR T-cell treatment with Blinatumomab. Stratified by illness severity and age, patients—n = 200 per group—have randomised therapy allocation. While Blinatumomab entails continuous intravenous infusion in six-week cycles, CAR T-cell treatment consists in lymphodepleting chemotherapy, T-cell collecting, genetic alteration, and reinfusion. Among the main results are remission rates, general survival, and progression-free survival. Strong statistical analysis, careful data collecting from electronic health records, and blinded outcome evaluations guarantee validity and repeatability of findings.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eResults\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eExamining 400 patients with relapsed/refractory DLBCL (200 CAR T-cell, 200 Blinatumomab) matched for age (mean: 61.4 years, SD ± 8.9), gender (57% vs. 55% male), BMI (27.6 vs. 27.9 kg/m²), and comorbidities, this study found With a greater complete remission rate (58% vs. 34%) and longer median progression-free survival (16.8 vs. 9.4 months, CAR T-cell treatment produced better results. But it caused severe CRS (78% vs. 48%), neurotoxicity (52% vs. 38%), and extended cytopenias (neutropenia: 62% vs. 44%). Though less hazardous, blinatumomab needed several cycles to be continuously effective. With sustained remissions (42% PFS at 24 months vs 18%), CAR T-cell treatment clearly has long-term benefits. Balancing effectiveness, toxicity, and patient-specific dangers, personalised therapy selection is crucial.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConclusion\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eHigher complete remission rates and longer PFS than Blinatumomab allow CAR T-cell treatment to offer better long-term disease management in relapsed/refractory DLBCL. Its increased toxicity load, however, calls for extensive care; Blinatumomab provides a less toxic, temporary substitute needing several cycles for long-term effectiveness.\u003c/p\u003e","manuscriptTitle":"Comparative Effectiveness of CAR T-Cell Therapy versus Blinatumomab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A prospective cohort study","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-02-28 16:53:28","doi":"10.21203/rs.3.rs-6104849/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"3326b248-87d5-4ce0-afdc-c4537aeeba84","owner":[],"postedDate":"February 28th, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[{"id":44845372,"name":"Stem Cell \u0026 Developmental Cell Biology"},{"id":44845373,"name":"Cancer Biology"},{"id":44845374,"name":"Medical Genetics"},{"id":44845375,"name":"Oncology"},{"id":44845376,"name":"Hematology"}],"tags":[],"updatedAt":"2025-02-28T16:53:28+00:00","versionOfRecord":[],"versionCreatedAt":"2025-02-28 16:53:28","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-6104849","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-6104849","identity":"rs-6104849","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}